==== Front Int J Mol Sci Int J Mol Sci ijms International Journal of Molecular Sciences 1422-0067 MDPI 33256121 10.3390/ijms21238979 ijms-21-08979 Review Understanding and Treating Niemann–Pick Type C Disease: Models Matter https://orcid.org/0000-0003-2511-6168Pallottini Valentina 1* https://orcid.org/0000-0001-7085-1431Pfrieger Frank W. 2* 1 Biomedical and Technology Science Section, Department of Science, Roma Tre University, Viale Marconi 446, 00146 Rome, Italy 2 Centre National de la Recherche Scientifique, Institut des Neurosciences Cellulaires et Intégratives, Université de Strasbourg, 8 Allée General Rouvillois, 67000 Strasbourg, France * Correspondence: valentina.pallottini@uniroma3.it (V.P.); fw-pfrieger@gmx.de (F.W.P.) 26 11 2020 12 2020 21 23 897906 10 2020 23 11 2020 © 2020 by the authors.2020Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).Biomedical research aims to understand the molecular mechanisms causing human diseases and to develop curative therapies. So far, these goals have been achieved for a small fraction of diseases, limiting factors being the availability, validity, and use of experimental models. Niemann–Pick type C (NPC) is a prime example for a disease that lacks a curative therapy despite substantial breakthroughs. This rare, fatal, and autosomal-recessive disorder is caused by defects in NPC1 or NPC2. These ubiquitously expressed proteins help cholesterol exit from the endosomal–lysosomal system. The dysfunction of either causes an aberrant accumulation of lipids with patients presenting a large range of disease onset, neurovisceral symptoms, and life span. Here, we note general aspects of experimental models, we describe the line-up used for NPC-related research and therapy development, and we provide an outlook on future topics. lysosomal disordercholesteroltransgeniccell cultureinduced pluripotent stem cellsneurodegenerationDrosophilazebrafishC. elegansfeline ==== Body 1. Niemann–Pick Type C Disease The prime purpose of biomedical research is to understand the molecular underpinnings of human diseases enabling the development of curative therapies. Unfortunately, these goals have been reached merely for a minuscule fraction of diseases. The large majority of ailments—affecting from just a handful of patients to millions worldwide—awaits a treatment [1,2,3]. There are numerous reasons for the slow progress such as rare occurrence, molecular complexity, and variability of symptoms. However, a decisive factor is the availability, quality, and use of experimental models [4,5,6,7,8,9,10,11,12,13]. NPC is a prime example for a disease that lacks a curative therapy despite impressive breakthroughs within the last decades [14,15,16,17] and rapidly growing publication counts (Appendix A, Figure 1). At first sight, the disease seems relatively easy to study and to understand: previous research showed that it is monogenic with autosomal-recessive inheritance and caused by mutations in either of two genes, NPC1 (OMIM #257220) [18] or NPC2 (OMIM #607625) [19,20]. The structures of the corresponding proteins [21,22,23,24,25] together with a wealth of cell-based data indicate that this duo collaborates to pilot unesterified cholesterol out of the endosomal–lysosomal system [26,27,28]. If the activity of the membrane-resident NPC1 or its intralumenal partner NPC2 is diminished or absent, unesterified cholesterol accumulates in compartments of the endosome-lysosome [29,30] together with other molecules [31,32]. How can this—at first sight well-defined—cellular problem cause havoc in humans presenting an enormous variability in disease onset, symptoms, and life span? In fact, NPC disease comprises several forms based on the age at which patients present neurological symptoms [14,20,33,34,35,36,37,38]. Rare peri- and neonatal cases present hepatosplenomegaly, jaundice, and fetal hydrops with rapid death often due to hepatic and respiratory failure [39,40,41,42,43,44]. Most patients show infantile forms presenting hypotonia and delayed motor development (early: <2 years) as well as clumsiness, speech delay, and cataplexy (late: 2–6 years) reaching life spans of several years [20,44,45]. The second largest group of patients shows the juvenile form (6–15 years) presenting cognitive impairment, ataxia, and dystonia [20,38,40,41,44]. The adolescent/adult form (>15 years) is characterized by cognitive impairment and psychiatric symptoms such as hallucinations and schizophrenia; the number of these patients is probably underestimated [14,20,46,47,48,49,50]. Notably, there is considerable overlap between the groups with respect to symptoms; many patients present common signs such as ataxia, dysphagia, and vertical supranuclear gaze palsy [20,38,41,44]. However, siblings bearing the same mutations can show distinct forms of the disease [20,33]. The diagnosis of NPC disease is complicated by the heterogeneous clinical presentation and therefore depends on laboratory tests. This includes the so-called filipin test, the detection of plasma biomarkers [51,52,53,54,55], and genetic analyses [56,57,58]. For decades, the filipin test represented the sine qua non to diagnose NPC. It requires primary cultures of fibroblasts from patient-derived skin biopsies followed by the staining of chemically fixed cells with filipin. This bacteria-derived, fluorescent complex of molecules binds unesterified cholesterol, thus allowing the visualization of its intracellular distribution [59]. Therapeutic options are limited to symptomatic treatment [14]. The only disease-modifying drug approved for NPC in many countries, except for the USA, is Miglustat/Zavesca (N-butyldeoxynojirimycin), which decelerates disease progression in some patients [38,60,61]. The drug also serves as FDA-approved substrate reduction therapy for Gaucher disease [62,63]. Understanding the somewhat mysterious links between cellular damage and the unpredictable outcome in patients, and the development of diagnostic tests and of efficient therapies require appropriate experimental approaches and models. In the following, we will make some general remarks, we will present currently available models for NPC research, and we will highlight crucial points. 2. The Use of Experimental Models in Biomedicine The use of experimental models in research has a long history. The first “publication” dates to the 17th century, when William Harvey described physiologic experiments with animals such as shrimp, eel, chick, and pigeon to understand blood circulation [64]. For centuries, it was believed that animals are unable to feel pain and that they resemble machines [65]. These views changed during the age of enlightenment: In 1789, the philosopher and jurist Jeremy Bentham was one of the first to raise the issue of animal protection by stating: “The question is not, Can they reason? or Can they talk? but, Can they suffer?” [66]. In 1876, the parliament of the United Kingdom passed the “Cruelty to Animals/Anti-Vivisection Act” that updated previous legislation and imposed rules on experiments with animals. The 20th century saw the establishment of three rules, named replacement, reduction, and refinement (the 3Rs) to match “the intimate relationship between humanity and efficiency in experimentation” [67]. These rules have become a key element of laws regulating the scientific use of animals worldwide [68]. Today, biomedical research on human diseases depends entirely on experimental models that range from single cells to non-human primates. Disease models may emerge from spontaneous changes. A famous example is the nude mouse (Mus musculus) introduced by Flanagan [69] and used extensively to create models requiring immunodeficiency, for example for patient-derived xenografts [70]. Models can also be based on healthy animals, in which a disease-like state is induced experimentally. Examples include pharmacologically-induced diabetes in rodents and rabbits [71,72], Parkinson-like symptoms in non-human primates [73] and autism-like behavior in rats (Rattus norvegicus) [74]. Other pathologic conditions such as stroke and retinal ischemia can be provoked by an artificial interruption of blood supply [75] and increase of intraocular pressure [76,77], respectively. Loss of bone mass mimicking osteoporosis occurs after tail immobilization in rats [78]. Meanwhile, most experimental disease models are generated by powerful genetic tools. Not surprisingly, oncology was the first area profiting from genetically modified mice with transgenic expression of oncogenes [79]. Mice are not the only species used to mimic human pathologies. The nematode Caenorhabditis elegans has been genetically modified to generate models of Parkinson’s [80], Alzheimer’s disease [81], PolyQ disease [82], and lysosomal disorders [83]. The fruit fly Drosophila melanogaster serves as disease model for different organs including the brain [84,85,86], kidney [87], and pancreas [88]. The usefulness of a model depends on the specific question. Ideally, the model accurately recapitulates key aspects of the disease of interest, for example pathologic changes in cells or symptoms of patients. Furthermore, it should allow extrapolating results to the target organism. Interestingly, history teaches that extrapolability does not necessarily scale with evolutionary kinship: closer may not be better. For example, thalidomide and aspirin are well tolerated by mammalian species but not by pregnant women [89], and chimpanzee have proven inappropriate for studies on AIDS [90]. Similarly, body size and metabolic rates do not always scale with disease processes. For example, some drugs can be effective at different dosages in different animal models [91,92] and humans [93]. In addition, some animals simply do not show specific symptoms: rats cannot really cough [94], rabbits (Oryctolagus cuniculus) and rats do not show some symptoms of cystic fibrosis [95], and no animal except for non-human primates displays endometriosis symptoms [96]. On the other hand, exotic species can serve as important models for human diseases. Examples are the armadillo Dasypus novemcinctus for research on leprosy [97], the turtle Trachemys scripta to study brain hypoxia and anoxia [98], and the pet Chinchilla lanigera to investigate hearing loss [99]. Diurnal rodents represent unique models of cone-related retinal diseases [100]. Disease models based on cultured cells have seen a remarkable renaissance due to the possibility of generating specific human cells from patient-derived induced pluripotent stem cells [101]. A recent article exemplifies this new approach going from in vitro data to retrospective analysis of clinical data exposing a possible treatment [102]. 3. Experimental Models for Niemann–Pick Type C1 and C2 Disease Numerous experimental models are available to study NPC disease [103], probably because the disease is monogenic, the transmission is recessive, and orthologues of the causative genes are present in many phyla ranging from plants to mammals [104] (Table 1). The models have driven the enormous progress in the field during the last decades. Most of them concern NPC1, which is mutated in 95% of patients. Only a few experimental models are available to study mutant NPC2. The presence of multiple isoforms in specific phyla suggests important and so far undiscovered functions of these proteins. Figure 2 indicates the use of the different models based on the number of publications (Appendix A). Clearly, the mouse has become the preferred workhorse in the NPC disease field. 3.1. Non-Mammalian Models The knock-out of NPC1 orthologues in plants (At1g42470, At4g38350; Arabidopsis thaliana) [105] and yeast (NCR1; Saccharomyces cerevisiae) [106] have been generated. Because both showed changes in sphingolipid, but not sterol metabolism, and because NPC2 orthologues were not known [107], it was assumed that the proteins have distinct roles across phyla. However, yeast cells bear a homologue of NPC2, which can replace the human version [108]. Moreover, yeast cells have been used to screen for pathways influencing the outcome of NPC1 deficiency [109,110,111] and to explore the molecular mechanism of sterol transfer based on structural data [25]. The knock-down of NPC1 and NPC2 homologues in the sterol auxotroph pathogen Entamoeba histolytica revealed their contribution to cholesterol uptake (Ehnpc1, Ehnpc2) [112]. The genome of Caenorhabditis elegans contains two homologues of mammalian NPC1 (ncr-1, ncr-2). Elimination of both forms stalls a specific phase of larval development, which is probably due to defects in the intracellular transport of cholesterol and the production of essential steroid hormones [113,114,115] (Table 1). The defects can be rescued by human NPC1L1 and NPC1 proteins [116] and by specific glycosphingolipids and endocannabinoids [117,118]. The elimination of Npc1a, one of two NPC1 homologues from Drosophila melanogaster, causes larval lethality (Table 1), which can be rescued by dietary supply of the steroid hormone ecdysone or by local expression of Npc1a in the ring gland [119,120]. The elimination of Npc1b also causes larval lethality due to defects in sterol absorption in the midgut (Table 1), which cannot be rescued by ecdysone [121]. The fruit fly bears a family of eight genes resembling NPC2. The simultaneous elimination of two of these genes, Npc2a and Npc2b, causes larval lethality and neurodegeneration, which again can be rescued by dietary cholesterol or ecdysone [122,123]. A genetic screen for pathways mediating cholesterol trafficking and steroidogenesis in Drosophila revealed that the activation of autophagy can overcome cholesterol accumulation due to NPC1 deficiency [124]. Induced models of NPC were created in the zebrafish Danio rerio (Table 1) using anti-oligonucleotide-based knock-down of npc1 [125,126]. These manipulations interfered with gastrulation and led to the premature death of embryos, which could be rescued by mouse Npc1 and in part by steroids [125]. Moreover, morpholino-based knock-down mimicked thrombopenia observed in human patients possibly due to defects in myeloid development [126]. CRISPR-CAS-induced null alleles of npc1 caused premature death with only a few animals surviving into adulthood. Mutant animals showed massive cholesterol accumulation and defects in the liver, cerebellum, and lateral line organ causing disturbed balance and motor control [127,128]. The non-mammalian models clearly matter, as they reveal how functions of NPC-related proteins evolved, they enable screens to identify NPC1- or NPC2-related pathways and processes, and they help to explore new therapeutic approaches. Up to now, their publication counts are lower than those of mammalian models (Figure 2). 3.2. Mammalian Models Of all mammalian species serving biomedical research, only mice and cats (Felis catus) are currently used to study NPC (Table 1). No rat or large animal model has been established for this disease. A single case report described NPC-like symptoms in a Boxer dog [149], and a recent study described calfs (Bos taurus) with progressive neurologic symptoms due to mutant NPC1, suggesting the possibility of a bovine model [144] (Table 1). The first mouse strains to study NPC carried spontaneous mutations in Npc1, namely the insertion of a retroposon (Nih allele, further referred to as Npc1Nih) [18,129] and of a 43 base-pair (spm allele, Npc1spm) [130,132] in BALB/c and C57BLKS/J colonies, respectively each causing a de facto Npc1 knock-out. These mice present a relatively early onset of the disease, which is characterized by hepatomegaly, weight loss, disturbed motor coordination, tremor, and ataxia. The mice die prematurely between 11 and 13 weeks of age (Table 1). Cells show an accumulation of unesterified cholesterol, gangliosides, and other lipids in different organs and tissues [132,150,151,152,153,154]. A similar phenotype was observed in a genetically modified mouse from the Goldstein/Brown lab. In this line (Npc1pf), a double mutation (P202A/F203A) abolishes cholesterol binding by NPC1 and invalidates its function, but it leaves its level and localization unaffected [131] (Table 1). The mice discussed so far represent one end of the model spectrum as they lack the NPC1 function completely and irreversibly. The complete absence of NPC1 occurs only in a small fraction of patients [45]. Nevertheless, these models mattered, as they enabled important discoveries including the gene responsible for the disease [18], the progressive neurodegeneration in the cerebellum [155,156,157], and links to autophagy [158,159,160] and Alzheimer’s disease [161]. Moreover, they were used extensively to explore new therapies (Table 2). More common NPC1 mutations in humans induce errors in the structure of the protein leading to its degradation but leave its function more or less intact. Mouse models mimicking these changes have appeared on the scene within the last ten years (Table 1). Maue and colleagues described a mouse line with a D1005G variant that was generated by ethyl nitrosourea mutagenesis (Npc1nmf164) [132]. Praggastis and colleagues presented a knock-in of the human I1061T version of NPC1 (Npc1I1061T) [133]. This model matters as it represents approximately 20% of all NPC cases [211,212]. The mouse strains bear misfolded NPC1, causing a partial loss of function. The onset of the disease is delayed, its progress is less severe, and the life span is extended to 17 weeks compared to the complete loss-of-function mutants [133] (Table 1). In 2017, two mouse strains bearing specific human mutations were presented together with a thorough characterization of their behavioral phenotypes [134]. The strains carry either an intronic point mutation (c.1554-1009G > A) generating a pseudoexon due to aberrant splicing (Npc1Imagine) or the c.1920delG mutation, generating a truncated protein (Npc1Pioneer) (Table 1). Homozygous Npc1Imagine mice and compound heterozygous animals Npc1Imagine/Pioneer displayed symptoms similar to those reported in other NPC animal models with an onset of first neurologic symptoms between 7 weeks and an average life span of 9 weeks. Notably, most homozygous Npc1Pioneer mice died during the embryonic stage; the few surviving mice (1–2%) were predominantly female [134]. The latest entry in the defilé of models bears a mutant Npc1 allele generated by the CRISPR-Cas technique (Npc1em1Pav) [135] (Table 1). These mice help address a key question in the field: which factors determine the enormous phenotypic variability observed in patients? Humans with the same mutation can present completely different disease onsets, progress, and life spans [213,214]. In mice, the outcome of a given mutation varies with the genetic background of strains [37,135,215,216,217,218]. Numerous double mutant mice have been created to test whether and how specific candidate genes impact the disease [163,173,177,190,191,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235]. Sex-dependent differences in behavior [236], life span [37,134], and responses to immune activation [237] and to potential therapies [171,238] were reported in some NPC1 mutant mice, raising the question of whether sex is a modifying factor in NPC disease [37] as in other cholesterol-related pathologies [239,240,241,242] and normal cholesterol homeostasis [243,244]. Several mouse models were established to study the relevance of NPC1 in specific cell types or tissues (Table 1). Using morula aggregation, so-called chimeric mouse lines were generated, in which distinct ratios of cells harbor the wild-type or the mutant allele [158]. Mice for the cell-specific elimination of Npc1 were based on the Cre/loxP technique (Npc1tm1.1Apl) [136,245,246] (Table 1). A first study showed that the elimination of Npc1 from Purkinje cells induces their degeneration but leaves the life span of mice unaffected [136]. A mouse model to study NPC1 deficiency in the liver forgoing neurologic complications was established by intra-peritoneal injections of antisense oligonucleotides in healthy BALB/c mice [137,186]. The over-expression of Npc1 in specific cell types has been accomplished using classic transgenic mice to target GFAP-expressing cells [138], the inducible TetOn/Off system, which was used to target neurons [139], and the Cre/loxP system allowing the cell-specific reversal of a Npc1 knock-out [140] (Table 1). These mice enable a cell- or tissue-specific rescue of NPC1 deficiency [218,247,248]. For example, the re-establishment of Npc1 expression in the liver rescued liver disease, but it did not prevent progressive neurodegeneration and premature death [140]. The use of cell-specific promoters requires a thorough validation of their expression patterns [249,250]. Moreover, the observation that NPC1 deficiency in neurons is sufficient to induce their death [158,245] does not exclude a demise-provoking contribution by non-neuronal cells such as microglia or astrocytes [251,252,253], serving potentially as therapeutic targets. Compared to Npc1, the line-up of mouse models targeting Npc2 is much smaller. The first mouse line was created by gene targeting, resulting in 4% of normal protein levels. These animals showed a similar phenotype as NPC1-deficient mice and as mice lacking both proteins. The latter finding provided first evidence for the functional cooperation between NPC1 and NPC2 in vivo [145]. Additional lines targeting Npc2 have been generated using the gene trap approach [146,147] (Table 1). The over-expression of Npc2 in the liver was accomplished using transgenic mice and specific promoter elements [148]. More mutant alleles of mouse Npc1 and Npc2 are listed on the MGI website. NPC-like symptoms in a domestic cat (Felis catus) were first reported by Lowenthal and collaborators [141] (Table 1). A colony was subsequently established, and the cats were further characterized. They develop neurologic symptoms such as ataxia and vestibular defects at juvenile age similar to humans, and they show neuroaxonal dystrophy [141,142,254,255,256,257,258]. In 2003, the genetic defect was uncovered: a single base substitution (2864G-C) in NPC1 causes an amino acid change (C955S) [143]. Two case reports described cats with distinct mutant alleles of NPC1 [259] and NPC2 [260], indicating that more feline NPC models could be established. 3.3. In Vitro Models Cultured cells are instrumental to uncover basic protein functions and molecular disease mechanisms and to test potential therapeutic approaches at the cellular level [12]. The use of cell cultures to study NPC disease dates back to the 1960s, when the Fredrickson group prepared primary fibroblasts from skin and bone marrow of patients with different forms of Niemann–Pick disease, including type C [261]. This pioneering publication initiated a decades-long series of studies based on patient-derived fibroblasts (Figure 3), enabling ground-breaking discoveries. Examples are the defect in cholesterol esterification and the accumulation of unesterified cholesterol [262,263,264], the functional validation of NPC1-encoding cDNA [265] and of secreted NPC2 [19], and the degradation of the misfolded p.I1061T NPC1 variant [266]. An alternative method to induce the cellular hallmark of NPC, an accumulation of unesterified cholesterol, relies on hydrophobic amines such as U18666A [267,268,269,270]. Originally, this molecule was developed as an inhibitor of cholesterol synthesis [271], and it was later shown to inhibit NPC1 activity directly [272]. 3.3.1. Cell-Lines The first cell lines to study NPC disease were established from patient-derived blood lymphocytes, which were immortalized through transformation by the Epstein–Barr virus [273]. A similar approach was used to immortalize lymphoid cells from NPC2 patients [153]. A fibroblast cell line based on the Npc1spm mouse was generated using a spontaneous immortalization (3T3) protocol [274,275]. Immortalized mouse embryonic fibroblasts from NPC1-deficient mice were transduced with different constructs to monitor autophagy [276]. A mouse embryonic fibroblast cell line from NPC2-deficient mice expressing a NPC2–crmCherry fusion protein was established to track the intracellular distribution of the protein [277]. A line of NPC2-deficient patient human fibroblasts showed a down-regulation of NPC1 upon infection with HIV [278]. Several models were derived from Chinese hamster ovary (CHO) cells, the workhorse of cell biology: NPC1-deficient CHO cells were generated using chemical or gene trap mutagenesis and assays to detect cholesterol transport-deficiency [279,280,281]. Other CHO lines stably over-express NPC1 [282,283], myc-tagged NPC2 [284], as well as NPC1-EGFP or -RFP fusion proteins [285,286,287], allowing for example to track the movement of NPC1-containing organelles [285]. CRISPR-Cas technology [288] or transfection with short interfering RNA constructs were used to generate NPC1- and NPC2-deficient HeLa [289,290,291,292] and Hek-293T cells [293]. The knock-down of NPC1 in a neuroblastoma cell line (SH-SY5Y) was achieved by stable transfection with short hairpin RNA [294]. Immortalized human hepatocytes and hepatic stellate cells with stable knock-down of NPC1 or NPC2 were obtained by transduction with lentivirus and short hairpin RNAs [295,296]. The artificial expression of NPC1 in Escherichia coli has been used to study its transport function [297]. In the context of Alzheimer disease research, NPC1 was stably down-regulated in a neuron-like Neuro-2a line that over-expresses a specific form of the amyloid precursor protein [298]. Schwann cell lines were derived using dorsal root ganglia and peripheral nerves of the Npc1spm mouse [299]. Knock-down in an oligodendroglial cell line was accomplished using short interfering RNA [200]. The first NPC model based on a haploid human cell line has been introduced recently [300]. Cell line-based models matter to uncover basic molecular functions of NPC1 [21] or NPC2 [301] and NPC1-dependent signaling pathways [293], to perform comparative studies at the cellular level [302], and to identify disease-relevant genes [289]. Cell lines helped to identify NPC1 as a receptor mediating Ebola virus infection [303,304] and to investigate its involvement in hepatitis C virus replication [305]. However, they cannot inform about cell-type specific dependency on NPC1 and consequences of its dysfunction. Moreover, it is not clear whether NPC1- or NPC2-related cellular processes observed in cell lines occur also in specialized cells in vivo. Another caveat derives from the fact that cell lines are per definitionem mitotic, whereas most differentiated cells in the body are post-mitotic. Cell division may modify how NPC1- or NPC2-deficiency affects cells. 3.3.2. Primary Cultures of Brain Cells An alternative to cell lines are primary cultures, where cells are isolated from the organism and used after different periods of culture without immortalization. Cultured cells retain their in vivo properties to degrees that depend on the cell type and the culture conditions, namely the artificial exposure to chemically undefined serum [306,307,308,309,310]. Most NPC patients suffer from debilitating neurologic symptoms and therefore, it appears imperative to study the impact of dysfunctional NPC1 or NPC2 on cells in the brain (Figure 3). The first studies using primary cultures of central nervous systen (CNS) cells investigated the expression and distribution of NPC1 in cerebellar neurons and glial cells [311] and reported defects in cholesterol metabolism and neurotrophin signaling in striatal neurons [312]. Thereafter, sympathetic [313], cortical [314], hippocampal [315,316] and retinal neurons [317] (Figure 4) as well as purified cerebellar Purkinje cells [318] have been studied in vitro. These models matter, as they revealed neuron-specific defects caused by NPC1 deficiency such as impaired synaptic function [316,318,319], depletion of cholesterol from axons, and an accumulation of cholesterol independently from lipoprotein uptake [313,317]. They also helped to identify lamellar inclusions as the site of cholesterol accumulation [317]. Cultured astrocytes [320], oligodendrocytes [321,322,323], and microglial cells [324,325] have rarely been studied, despite the potential glial involvement in neurodegeneration [251], evidence for myelination defects [246], and signs of neuroinflammation in NPC disease [326]. Organotypic cultures represent a more integrated preparation to study neurons, but they have been used only sporadically in this field [325,327]. 3.3.3. Primary Cultures of Other Cells Predominant in vitro models of NPC research are the above-mentioned patient-derived skin fibroblasts, which are mitotic primary cells, but not cell lines unless they have been immortalized. Only very few differentiated cell types are studied in the field (Figure 3). Liver and spleen are affected in many NPC patients, but few reports used primary hepatocytes [199,328,329] and hepatic stellate (Ito) cells [330] from NPC1-deficient mice, splenocytes from NPC2-deficient mice [146], and NPC1-deficient splenic B cells [331]. Acutely isolated Kupffer cells were examined in chimeric mice following bone marrow transplantation [332]. With respect to lung defects, one report studied primary type 2 pneumocytes treated with U18666A [333]. With respect to immune cells, studies used NPC1-deficient macrophages [328,332,334], invariant Natural Killer T cells and human B cell lines [335], lymphoblasts [275], monocyte-derived dendritic cells [336], and T cells [146,337,338]. To date, no studies on cultured leukocytes or granulocytes have been published. Among other cells, the effects of NPC2 knock-down on adipocyte differentiation and function were studied using primary cultures [339], and spermatozoa from NPC2-deficient mice were isolated and analyzed [340]. 3.3.4. Stem Cell-Derived Models The differentiation of specific cell types from embryonic or induced stem cells has become popular, because this technology allows studying cells from patients and producing them in large quantities. Consequently, the number of publications related to these models in the NPC field is increasing (Figure 3). A first report showed the impaired self-renewal and differentiation of neural stem cells from embryonic brains of NPC1-deficient mice [341]. Ordonez and colleagues created a short hairpin RNA-based knock-down of NPC1 in human embryonic stem cells and differentiated these cells to neurons [342]. These neurons recapitulated the pathologic hallmark of NPC, the accumulation of unesterified cholesterol, and showed impaired mitochondrial function and defective autophagy. Multipotent adult stem cells were isolated from skin biopsies of NPC patients and control subjects and differentiated to neurons showing an accumulation of cholesterol [343]. These cells were selected by specific culture conditions. An alternative and meanwhile standard approach is the reprogramming of cells from adult tissues to create induced pluripotent stem cells and their subsequent differentiation to specialized, often postmitotic cells. Several studies used this approach to generate neurons from NPC patients and healthy donors [344,345,346,347,348,349]. Maetzel and colleagues also generated stem cell-derived hepatic cells and isogenic control lines to avoid confounding effects by distinct genetic backgrounds of patients and donors [346]. The stem cell-derived models matter: they enable studying the impact of NPC1 or NPC2 deficiency on differentiated human cells, notably neurons, and to explore new therapeutic strategies [347,350,351]. However, the protocols for reprogramming and differentiation need to be standardized to allow for comparison of results. 4. Models Mattering for Therapy Development Experimental models are indispensable for the preclinical exploration of therapeutic approaches. In the NPC field, cell-based screens for targets and drugs used yeast [109], immortalized embryonic fibroblasts [276] or ovarian granulosa cells from mutant mice [352], human stem cell-derived neurons [347,348,350,351,353,354], mutant CHO lines [355], and patient-derived fibroblasts [356,357]. Numerous therapeutic approaches were tested in vivo using NPC mice and cats. Table 2 lists studies where the impact of treatments on disease progression was assessed with proper controls. Few studies have delivered an approved drug or treatments reaching clinical development. The disease-modifying N-butyldeoxynojirimycin inhibits glucosylceramide synthase [358]. Curiously, a first in vitro study on CHO cells showed that the compound does not revert cholesterol accumulation in NPC1-deficient cells [359]. This was also observed in stem cell-derived neurons in vitro [347], arguing against a therapeutic effect. However, in vivo studies showed that the drug slows down neurologic disease progression and prolongs the life span of NPC1-deficient BALB/c mice and NPC1 mutant cats [184,360], providing preclinical evidence for its therapeutic use (Table 2). A potential treatment is based on 2-hydroxypropyl-beta-cyclodextrin (CD) that chelates cholesterol and other components [361] (Table 2). Curiously, the exploration of this compound started with in vivo experiments—again with discouraging results. A first study using intra-peritoneal or intra-thecal injection in NPC1-deficient mice failed to show a positive effect [362]. However, subsequent reports revealed that CD prolongs the life span, slows down neurologic disease progression, and halts the degeneration of Purkinje cells in the mouse and cat model [177,178,179,180,181,363,364]. Intra-thecal injections were required, as CD cannot pass the blood–brain barrier [365]. NPC1-deficient mice were also used to study ototoxicity of CD [366,367] and its effects on microglial cells [368] and the liver [369]. Effects of CD on NPC1-deficient cells were explored in lateral line neuromast cells in vivo [128], siRNA-treated HeLa cells [370], liver-derived cell lines [371], cultured fibroblasts [372,373,374], and primary [317,375,376] or stem cell-derived neurons [342,353,377]. First clinical data showed that CD decelerates disease progression in patients [378,379]. Histone deacetylases (HDACs) emerged as a possible therapeutic target for NPC from a genetic screen in yeast [109] and from in vitro studies of NPC1-deficient neuronal stem cells [380], patient- and mutant mouse-derived fibroblasts [133,357,374,381,382,383,384], cell lines [384,385], and U18666A-treated hippocampal neurons [386]. A first in vivo study using Npc1 mutant mice claimed that repeated intra-peritoneal injections of vorinostat, an HDAC inhibitor, together with polyetheylene–glycol and CD slow down neurologic disease progression, but some controls were missing [387]. A subsequent report on mice attributed the effects on neurologic symptoms to CD [363]. Repeated intra-peritoneal injections of vorinostat in NPC1 mutant mice improved liver function but did not slow down weight loss or increase life span [194] probably because the drug cannot enter the central nervous system [363]. A comparison of drug effects using different mouse models revealed that drug effects on liver function were not mediated by proteostatic effects on NPC1 [194] (Table 2). Evidence from Npc1 mutant mice that heat-shock proteins protect Purkinje cells from degeneration suggested these components as new drug targets in NPC [157,227]. The idea was supported by in vitro studies on patient-derived fibroblasts [193,227,388] and U18666A-treated neurons [227] and in vivo studies exploring the over-expression or knock-down of heat shock protein beta-1 in NPC1-deficient mice [227]. A corresponding disease-modifying therapy may be based on arimoclomol, a small molecule enhancer of heat shock proteins, whose effects were explored in patient-derived fibroblasts and NPC1-deficient mice [193] (Table 2). Within the last years, NPC1-deficient mice also helped to explore gene therapy for NPC (Table 2). First support for this approach came from two observations. The over-expression of NPC1 in brain cells was achieved following the intra-cerebral injection of an adenoviral construct in vivo [389]. The cell-specific over-expression of NPC1 in transgenic mice rescued pathologic changes due to NPC1 deficiency [139,390]. Within the last few years, a series of studies showed that the progress of neurologic disease in NPC1-deficient mice is slowed down by intra-cardiac [195], intra-cisternal [196], and intra-cerebroventricular [197] injection of vectors based on adeno-associated virus 9 (AAV9). Similar improvements were found in mice lacking NPC2 following intra-cisternal injections of AAVrh.10 carrying NPC2 [198]. 5. Conclusions and Outlook The diversity and validity of experimental models and their pertinence to topics of interest are key to advance biomedical research. Over the last decades, the NPC field has developed a gang of models that matter as they revealed the origin of the disease, provided important insight in disease mechanisms, and helped to explore new diagnostic and therapeutic approaches. Moreover, these models are used extensively outside the NPC field to understand fundamental aspects of cholesterol homeostasis [391] in different organs, notably the brain [392], and mechanisms of other cholesterol-related diseases [393,394,395]. The publication record indicates a clear preference for NPC1, mice, and fibroblasts as gene, animal, and cell of choice, respectively. A few points should be considered with respect to future developments and advances. The focus on NPC1 is understandable given that most patients bear mutations in this gene. However, new models targeting NPC2 are of high interest, as they can help for example to discern NPC1- and NPC2-dependent genetic, epigenetic, and sex-dependent disease modifiers. The identification of modifiers remains a top priority in the field. The predominance of mouse models in NPC research is readily explained by the increasing ease of genetic manipulations and the relative cost efficacy. However, mice impose several limitations, notably with respect to their small size and their limited behavioral repertoire [396]. Therefore, new models based on larger mammals including rats are highly desirable last but not least to enable the successful translation of therapeutic approaches into the clinic [6]. There is also a clear demand for inducible/reversible pharmacologic models based on highly selective small molecule inhibitors of NPC1 or NPC2. These approaches would allow for before/after studies and thereby help to discern within-subject variability. The surprising discovery that NPC1 serves as receptor for filovirus entry into cells [303,304] will help to develop such inhibitors and new models. The focus on fibroblasts originates from their availability through skin biopsies, their ease of maintenance, and their long-standing use as a diagnostic tool. However, studies of patient-derived fibroblasts cannot inform about the outcome of NPC1 dysfunction in highly specialized postmitotic cells such as neurons. Therefore, it is imperative to elucidate how specific cells, namely the most vulnerable, react to defects in NPC1 and NPC2. This will require a combination of preparations allowing to study the same type of cells in vivo, ex vivo, and in vitro (Figure 4) as well as new approaches to analyze mRNA, protein, and lipid content of defined cell types replacing transcriptomic, proteomic, and lipidomic studies of entire organs or tissues. As an example, acutely isolated cells combined with single cell transcriptomics [231] represent a first step that needs to be refined and extended with a focus on vulnerable cells in most affected organs, including the brain, liver, and lung. Cells differentiated from induced pluripotent stem cells represent an alternative although with caveats [397]. Whatever the source of cells, advanced culture systems preserving their three-dimensional arrangement should be considered as well [398,399]. The development of therapeutic approaches for neurologic and psychiatric symptoms faces fundamental hurdles with respect to diagnosis and model validity that are not specific to NPC [400,401]. Clearly, the establishment of new models requires substantial investments and bears risks, but ultimately, all that matters are the models: they are indispensable to expose molecular mechanisms underlying the disease and to develop efficient therapies. Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Author Contributions Conceptualization, V.P. and F.W.P.; methodology, F.W.P.; software, F.W.P.; visualization, F.W.P; writing—original draft preparation, V.P. and F.W.P.; writing—review and editing, V.P. and F.W.P. All authors have read and agreed to the published version of the manuscript. Funding The APC for this review was funded by the Niemann-Pick Selbsthilfegruppe e.V. (Germany). The authors’ research is funded by Together Strong NPC Foundation (V.P.), Niemann-Pick Selbsthilfegruppe e.V., Ara Parseghian Medical Research Foundation and Bild hilft e.V. “Ein Herz für Kinder” (F.W.P.). Conflicts of Interest The authors declare no conflict of interest. Appendix A To obtain quantitative data on the publication output in the field, Boolean queries were performed in PubMed and records were downloaded in csv format. Data analysis and visualization were accomplished using the open source software R [402] and selected R packages (data.table [403], ggplot2 [404], readr [405]. Figure 1 Growth of the NPC research field. Cumulative counts of publications obtained by Boolean queries in PubMed using the keywords “Niemann–Pick type c OR Niemann–Pick type c1 OR Niemann-Pick type c2 OR npc1 OR npc2” (Appendix A). Black and orange lines indicate original articles “(...) NOT review [pt]” and reviews [pt] “(...) AND review [pt]”, respectively. To retrieve publications more specifically related to NPC, we restricted the query to titles [ti] or abstracts [ab] by adding the corresponding field tags to each keyword “Niemann–Pick type c [tiab] OR Niemann–Pick type c1 [tiab] OR Niemann–Pick type c2 [tiab] OR npc1 [tiab] OR npc2 [tiab]”. Sky blue and green lines indicate original articles and reviews of this subset, respectively. Figure 2 Use of experimental models in NPC research. Cumulative counts (log10 values) of publications obtained by respective Boolean queries in PubMed [e.g., for mouse: (Niemann–Pick type c [tiab] OR Niemann–Pick type c1 [tiab] OR Niemann–Pick type c2 [tiab] OR npc1 [tiab] OR npc2 [tiab]) AND (mice [tiab] OR mouse [tiab] OR mus musculus [tiab]) NOT review]. Inset, the histogram shows that most publications relate to one animal model and that only a small fraction of articles contributes to multiple cumulative counts. Figure 3 NPC research on specific types of cells. Cumulative counts of publications obtained by respective Boolean queries in PubMed [e.g., for fibroblasts: (Niemann–Pick type c[tiab] OR Niemann–Pick type c1[tiab] OR Niemann–Pick type c2[tiab] OR npc1[tiab] OR npc2[tiab]) AND (fibroblast[tiab] OR fibroblasts[tiab]) NOT review]. Inset, the histogram shows that most publications relate to one cell model and that only a small fraction of articles contributes to multiple cumulative counts. Figure 4 Models to study the impact of NPC1 deficiency on selected neurons in the retina. (a) Fluorescence micrographs of retinal neurons from one-week-old wild-type (WT) and NPC1-deficient (NPC) mice in vivo. NPC1 deficiency causes an intracellular accumulation of unesterified cholesterol in neurons of the ganglion cell layer in vivo (arrowheads). (b) Phase-contrast (left) and fluorescence micrographs (middle, right) of retinal neurons acutely isolated from one-week-old wild-type (WT: left, middle) and NPC1-deficient mice (NPC). In this ex vivo model, NPC1-deficient neurons maintain the increased levels of cholesterol as shown by filipin staining. (c) Phase-contrast (left) and fluorescence micrographs (middle, right) of neurons purified from the retina of one-week-old rats, cultured for 48 h and stained with filipin. Treatment with the NPC1-inhibiting drug U18666A induced an accumulation of unesterified cholesterol. Scale bars: 20 µm. In (a–c), the distribution of unesterified cholesterol was shown by the staining of chemically fixed material with filipin (a,b): Barthélémy, Pfrieger, unpublished; (c): modified from [317]. ijms-21-08979-t001_Table 1Table 1 Animal models available to study NPC disease. Species, Gene, Animal model Symptom Onset Life Span Visceral Symptoms Neurologic Symptoms Lipid Accumulation in Tissues References Caenorhabditis elegans ncr-1 ncr-1(nr2022) ncr-2 ncr-2(nr2023) ND Dauer formation ND Modified trafficking or release of synaptic vesicles Nerve ring, spermatheca and oocytes: DHE accumulation [113,114,115] Drosophila melanogaster Npc1a Npc1a57A ND Larval lethality More efficient sterol absorption than wild-type animals ND Malpighian tubules and midgut: Sterol accumulation. Brain and retina: Chol aggregates [119,120] Drosophila melanogaster Npc1b Npc1bR9-28 ND Larval lethality Defects in sterol absorption; similar to NPC1L1 ND No Chol accumulation [121] Drosophila melanogaster Npc2a Npc2a376 Npc2b Npc2b19 ND Larval lethality Apoptotic cell death in the nervous system No sterol distribution abnormality [122,123] Danio rerio npc1 npc1ihb334 npc1ihb335 npc1hg37 npc1y535 Larval stage 99% animals die within the first MPF; 1% die before 8 months of age Hepatomegaly, splenomegaly Disturbed balance and motor control, loss of Purkinje cells Liver: accumulation of Chol, CER, DG, LPA, PA, PC, PE, PS, TG, SL [125,126,127,128] Mus musculus Npc1 BALB/cNctr-Npc1m1n/J Npc1nih 6 wks (N) 9–11 wks Hepatomegaly, splenomegaly, decreased weight gain, increased lung mass Disturbed motor coordination, tremor, ataxia, loss of Purkinje cells Spleen, liver, lung, lymph nodes, thymus, bone marrow, brain: accumulation of FA, CER, Chol, SL [18,129] Mus musculus C57BLKS/J-Npc1spm/J Npc1spm 4 wks (V) 11–15 wks Hepatomegaly, splenomegaly, decreased weight gain Disturbed motor coordination, tremor, ataxia, loss of Purkinje cells Liver: accumulation of FA, CER, Chol, SL. Brain: Chol accumulation [130] Mus musculus Npc1tm1Mbjg Npc1pf 7 wks (N) 12 wks Hepatomegaly, splenomegaly, decreased weight gain Tremor, ataxia, loss of Purkinje cells Brain, kidney, liver, lung, and spleen: Chol accumulation. Brain and liver: GM accumulation. [131] Mus musculus Npc1nmf164/J Npc1nmf164 4 wks (N) 16 wks Hepatomegaly, splenomegaly, decreased weight gain, foamy pulmonary macrophages Loss of Purkinje cells, abnormal acoustic startle response, decreased strength and motor capabilities Brain: Chol and GM accumulation. Liver: accumulation of CER, Chol, SL, GM. [132] Mus musculus Npc1tm(I1061T)Dso Npc1I1061T 8 wks (N) 17–18 wks ND Decreased weight gain Decreased motor coordination, tremor, loss of Purkinje cells Liver and brain: Chol accumulation [133] Mus musculus Npc1tm1Tacf/J Npc1Imagine/Imagine 7 wks (N) 9 wks ND Decreased motor coordination, tremor, ataxia, age-dependent hyperactivity, reduced anxiety, cortico-hippocampal defects, higher pain threshold ND [134] Mus musculus Npc1tm2Tacf/J Npc1Pioneer/Pioneer ND Only 2% live births ND ND ND [134] Mus musculus Npc1Imagine/Pioneer 7 wks (N) 9 wks ND Decreased motor coordination, tremor, ataxia, age-dependent hyperactivity, reduced anxiety, higher pain threshold Liver: Chol and CER accumulation Brain: Chol, CER, GM accumulation [134] Mus musculus Npc1em1Pav 4 wks (V,N) 10–12 wks, strain-dependent ND Loss of Purkinje cells, decreased motor coordination Liver, brain, spleen: GM accumulation [135] Mus musculus Npc1tm1.1Apl Cell-specific knock-out based on Cre/loxP Depends on target cells/tissues [136] Mus musculus Npc1(ASO) Knock-down of NPC1 in liver and lung by antisense oligonucleotides (ASOs) Hepatomegaly; foamy, vacuolated macrophages and increased apoptosis/proliferation in liver No neurologic symptoms Liver: Chol accumulation [137] Mus musculus Tg(Gfap-Npc1) Rescue of Npc1 expression in Gfap-expressing cells Delayed onset with respect to NPC1-/- (N) 24 wks Weight gain with respect to NPC1-/- Reduced numbers of axonal spheroids and reactive astrocytes, restoration of myelin, loss of Purkinje cells, decreased neurodegeneration with respect to NPC1-/- Reduced Chol accumulation in some brain areas with respect to NPC1-/- [138] Mus musculus Tg(tetO-Npc1/YFP)1Mps Cell-specific over-expression based on Tet-On/Off Depends on target cells/tissues [139] Mus musculus Npc1fl/fl Cell-specific reversal of Npc1 knock-out based on Cre/loxP Depends on target cells/tissue [140] Felis catus NPC1 6 wks (N) 20 wks Hepatomegaly, spleen and lung with multifocal histiocytosis Tremor, ataxia, loss of Purkinje cells, astroglyosis, myelin abnormalities in peripheral nervous system Pyramidal neurons: GM2 accumulation [141,142,143] Bos taurus NPC1 3 months (N) before 8 months (N = 1) Marked hypertrophy of Purkinje cells in heart, foamy macrophages in lymph nodes Limb weakness, dysmetria, incoordination, a wide based stance, walking sideways or falling over and recumbency, vacuolation of Purkinje cells, astrocytosis, microgliosis Fibroblasts: Chol, GM, SL accumulation [144] Mus musculus Npc2tm1Plob 4 wks (V) 18 wks Decreased weight gain Tremor, motor defects, ataxia, loss of Purkinje cells Liver: Chol accumulation, neocortex, dentate gyrus, hippocampus, and cerebellum: Chol accumulation [145] Mus musculus Npc2Gt(LST105)Byg 8 wks (N) ND Decreased weight gain Tremor, ataxia, loss of Purkinje cell, astrocytosis Liver, spleen, kidney, lung: Chol accumulation. [146,147] Mus musculus Tg(Apoe-Npc2) Over-expression of NPC2 in liver ND ND [148] Abbreviations: not determined (ND); weeks (wks); neurological symptoms (N); visceral symptoms (V); cholesterol (Chol); ceramide (CER); dehydroergosterol (DHE); diacylglycerol (DG); gangliosides (GM); lysophosphatidic acid (LPA); months post fertilization (MPF); phosphatidic acid (PA); phosphatidyl–choline (PC); phosphatidyl–ethanolamine (PE); phosphatidyl–serine (PS); sphingolipids (SL); triglycerides (TG) ijms-21-08979-t002_Table 2Table 2 Summary of therapeutic approaches for NPC explored with animal models. Treatment Model Effect Reference Cholesterol lowering drugs Npc1nih No [162] Apoptosis, inhibition Npc1nih No [163] Mitogen-activated protein kinase, inhibition Npc1nih No [164] Dietary restriction Cat No [165] Implantation of neural stem cells Npc1nih No [166] Transplantation of mesenchymal stem cell Npc1nih Small [167,168,169] Vitamin C Npc1nih No [170] Vitamin E Npc1nih Yes [171,172] Liver X receptor, activation Npc1nih Yes [173] Pregnane X receptor, activation Npc1nih Yes [174] Estradiol Npc1nih Small [175] C-Abl inhibition (Imatinib) Npc1nih Yes [176] 2-hydroxypropyl-beta-cyclodextrin Npc1nih, cat Yes [177,178,179,180,181] Cyclin-dependent kinase-5, inhibition Npc1nih Small [182] Non-steroidal anti-inflammatory drugs Npc1nih Yes [170] Protein replacement, NPC2 129P2/OlaHsd-Npc2Gt(LST105)BygNya Small [147] Curcumin Npc1nih No [183] Glucosylceramide synthase, inhibition Npc1nih, cat Yes [184,185] N-acetylcysteine Npc1nih, Npc1(ASO) Small [186] Copper chelation Npc1nih Yes, not CNS [187] Acetylcholinesterase, inhibition Npc1nih Small [188] Combination miglustat, curcumin, ibuprofen Npc1nih Yes [189] Glucocerebrosidase, inhibition Npc1nih Yes [190] Necroptosis, inhibition Npc1nih Yes [191,192] Heat shock protein, activation (Arimoclomol) Npc1nih Yes [193] Histone deacetylases, inhibition (Vorinostat) Npc1nmf164, Npc1nih Yes, not CNS [194] Gene therapy, AAV9-NPC1 Npc1nih Yes [195,196,197] Gene therapy, AAV rh.10-NPC2 Npc2tm1Plob Yes [198] Glutathion Npc1nih Yes [199] Adenosine A2A receptor, activation Npc1nih Yes [200] Polymeric beta-cyclodextrin Npc1 nmf164 Small [201] Pneumococcal immunization Npc1nih Yes [202] Histamine H3 receptor, activation Npc1nih No [203] 6-O-alpha-maltosyl-beta-cyclodextrin Npc1nih Yes [204] Implantation of VEGF-overexpressing neural stem cells Npc1nih Yes [205] CYP46A1, activation Npc1 nmf164 Yes [206] High-density lipoprotein nanoparticles Npc1 I1061T Small [207] Gene therapy, AAV-mediated base editing Npc1 I1061T small [208] Iron chelation Npc1nih No [209] Gene therapy, Trojan horse liposomes Npc1nih No [210] ==== Refs References 1. Boycott K.M. Vanstone M.R. Bulman D.E. MacKenzie A.E. Rare-disease genetics in the era of next-generation sequencing: Discovery to translation Nat. Rev. Genet. 2013 14 681 691 10.1038/nrg3555 23999272 2. Ruz C. Alcantud J.L. Vives Montero F. Duran R. Bandres-Ciga S. Proteotoxicity and Neurodegenerative Diseases Int. J. Mol. Sci. 2020 21 5646 10.3390/ijms21165646 3. Tanner L. Single A.B. Animal Models Reflecting Chronic Obstructive Pulmonary Disease and Related Respiratory Disorders: Translating Pre-Clinical Data into Clinical Relevance J. Innate Immun. 2020 12 203 225 10.1159/000502489 31527372 4. Justice M.J. Dhillon P. Using the mouse to model human disease: Increasing validity and reproducibility Dis. Model. Mech. 2016 9 101 103 10.1242/dmm.024547 26839397 5. Cacheiro P. Haendel M.A. Smedley D. New models for human disease from the International Mouse Phenotyping Consortium Mamm. Genome 2019 30 143 150 10.1007/s00335-019-09804-5 31127358 6. Gurda B.L. Vite C.H. Large animal models contribute to the development of therapies for central and peripheral nervous system dysfunction in patients with lysosomal storage diseases Hum. Mol. Genet. 2019 28 R119 R131 10.1093/hmg/ddz127 31384936 7. Madeja Z.E. Pawlak P. Piliszek A. Beyond the mouse: Non-rodent animal models for study of early mammalian development and biomedical research Int. J. Dev. Biol. 2019 63 187 201 10.1387/ijdb.180414ap 31058296 8. Smith J.R. Bolton E.R. Dwinell M.R. The Rat: A Model Used in Biomedical Research Methods Mol. Biol. 2019 2018 1 41 31228150 9. Breuer M. Patten S.A. A Great Catch for Investigating Inborn Errors of Metabolism-Insights Obtained from Zebrafish Biomolecules 2020 10 1352 10.3390/biom10091352 10. Favret J.M. Weinstock N.I. Feltri M.L. Shin D. Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases Front. Mol. Biosci. 2020 7 57 10.3389/fmolb.2020.00057 32351971 11. Kruczek K. Swaroop A. Pluripotent stem cell-derived retinal organoids for disease modeling and development of therapies Stem. Cells 2020 38 1206 1215 10.1002/stem.3239 32506758 12. Slanzi A. Iannoto G. Rossi B. Zenaro E. Constantin G. In vitro Models of Neurodegenerative Diseases Front. Cell Dev. Biol. 2020 8 328 10.3389/fcell.2020.00328 32528949 13. Tomioka I. Nagai Y. Seki K. Generation of Common Marmoset Model Lines of Spinocerebellar Ataxia Type 3 Front. Neurosci. 2020 14 548002 10.3389/fnins.2020.548002 33071733 14. Geberhiwot T. Moro A. Dardis A. Ramaswami U. Sirrs S. Marfa M.P. Vanier M.T. Walterfang M. Bolton S. Dawson C. Consensus clinical management guidelines for Niemann-Pick disease type C Orphanet J. Rare Dis. 2018 13 50 10.1186/s13023-018-0785-7 29625568 15. Bräuer A.U. Kuhla A. Holzmann C. Wree A. Witt M. Current Challenges in Understanding the Cellular and Molecular Mechanisms in Niemann-Pick Disease Type C1 Int. J. Mol. Sci. 2019 20 4392 10.3390/ijms20184392 31500175 16. Hammond N. Munkacsi A.B. Sturley S.L. The complexity of a monogenic neurodegenerative disease: More than two decades of therapeutic driven research into Niemann-Pick type C disease Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2019 1864 1109 1123 10.1016/j.bbalip.2019.04.002 31002946 17. Wheeler S. Sillence D.J. Niemann-Pick type C disease: Cellular pathology and pharmacotherapy J. Neurochem. 2020 153 674 692 10.1111/jnc.14895 31608980 18. Loftus S.K. Morris J.A. Carstea E.D. Gu J.Z. Cummings C. Brown A. Ellison J. Ohno K. Rosenfeld M.A. Tagle D.A. Murine model of Niemann-Pick C disease: Mutation in a cholesterol homeostasis gene Science 1997 277 232 235 10.1126/science.277.5323.232 9211850 19. Naureckiene S. Sleat D. Lackland H. Fensom A. Vanier M.T. Wattiaux R. Jadot M. Lobel P. Identification of HE1 as the Second Gene of Niemann-Pick C Disease Science 2000 290 2298 2301 10.1126/science.290.5500.2298 11125141 20. Vanier M. Niemann-Pick disease type C Mol. Chem. Neuropathol. 1996 27 70 72 10.1007/BF02815049 21. Kwon H.J. Abi-Mosleh L. Wang M.L. Deisenhofer J. Goldstein J.L. Brown M.S. Infante R.E. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol Cell 2009 137 1213 1224 10.1016/j.cell.2009.03.049 19563754 22. Gong X. Qian H. Zhou X. Wu J. Wan T. Cao P. Huang W. Zhao X. Wang X. Wang P. Structural Insights into the Niemann-Pick C1 (NPC1)-Mediated Cholesterol Transfer and Ebola Infection Cell 2016 165 1467 1478 10.1016/j.cell.2016.05.022 27238017 23. Li X. Wang J. Coutavas E. Shi H. Hao Q. Blobel G. Structure of human Niemann-Pick C1 protein Proc. Natl. Acad. Sci. USA 2016 113 8212 8217 10.1073/pnas.1607795113 27307437 24. Li X. Lu F. Trinh M.N. Schmiege P. Seemann J. Wang J. Blobel G. 3.3 Å structure of Niemann-Pick C1 protein reveals insights into the function of the C-terminal luminal domain in cholesterol transport Proc. Natl. Acad. Sci. USA 2017 114 9116 9121 10.1073/pnas.1711716114 28784760 25. Winkler M.B.L. Kidmose R.T. Szomek M. Thaysen K. Rawson S. Muench S.P. Wüstner D. Pedersen B.P. Structural Insight into Eukaryotic Sterol Transport through Niemann-Pick Type C Proteins Cell 2019 179 485 497.e418 10.1016/j.cell.2019.08.038 31543266 26. Pfisterer S.G. Peränen J. Ikonen E. LDL-cholesterol transport to the endoplasmic reticulum: Current concepts Curr. Opin. Lipidol. 2016 27 282 287 10.1097/MOL.0000000000000292 27054443 27. Pfeffer S.R. NPC intracellular cholesterol transporter 1 (NPC1)-mediated cholesterol export from lysosomes J. Biol. Chem. 2019 294 1706 1709 10.1074/jbc.TM118.004165 30710017 28. Meng Y. Heybrock S. Neculai D. Saftig P. Cholesterol Handling in Lysosomes and Beyond Trends Cell Biol. 2020 30 452 466 10.1016/j.tcb.2020.02.007 32413315 29. Sokol J. Blanchette-Mackie J. Kruth H.S. Dwyer N.K. Amende L.M. Butler J.D. Robinson E. Patel S. Brady R.O. Comly M.E. Type C Niemann-Pick disease. Lysosomal accumulation and defective intracellular mobilization of low density lipoprotein cholesterol J. Biol. Chem. 1988 263 3411 3417 3277970 30. Liscum L. Ruggiero R.M. Faust J.R. The intracellular transport of low density lipoprotein-derived cholesterol is defective in Niemann-Pick type C fibroblasts J.Cell Biol. 1989 108 1625 1636 10.1083/jcb.108.5.1625 2715172 31. Breiden B. Sandhoff K. Mechanism of Secondary Ganglioside and Lipid Accumulation in Lysosomal Disease Int. J. Mol. Sci. 2020 21 2566 10.3390/ijms21072566 32. Lloyd-Evans E. Morgan A.J. He X. Smith D.A. Elliot-Smith E. Sillence D.J. Churchill G.C. Schuchman E.H. Galione A. Platt F.M. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium Nat. Med. 2008 14 1247 1255 10.1038/nm.1876 18953351 33. Patterson M.C. Hendriksz C.J. Walterfang M. Sedel F. Vanier M.T. Wijburg F. Recommendations for the diagnosis and management of Niemann-Pick disease type C: An update Mol. Genet. Metab. 2012 106 330 344 10.1016/j.ymgme.2012.03.012 22572546 34. Patterson M.C. Mengel E. Wijburg F.A. Muller A. Schwierin B. Drevon H. Vanier M.T. Pineda M. Disease and patient characteristics in NP-C patients: Findings from an international disease registry Orphanet J. Rare Dis. 2013 8 12 10.1186/1750-1172-8-12 23324478 35. Mengel E. Klünemann H.H. Lourenço C.M. Hendriksz C.J. Sedel F. Walterfang M. Kolb S.A. Niemann-Pick disease type C symptomatology: An expert-based clinical description Orphanet J. Rare Dis. 2013 8 166 10.1186/1750-1172-8-166 24135395 36. Mengel E. Pineda M. Hendriksz C.J. Walterfang M. Torres J.V. Kolb S.A. Differences in Niemann-Pick disease Type C symptomatology observed in patients of different ages Mol. Genet. Metab. 2017 120 180 189 10.1016/j.ymgme.2016.12.003 27993458 37. Bianconi S.E. Hammond D.I. Farhat N.Y. Dang Do A. Jenkins K. Cougnoux A. Martin K. Porter F.D. Evaluation of age of death in Niemann-Pick disease, type C: Utility of disease support group websites to understand natural history Mol. Genet. Metab. 2019 126 466 469 10.1016/j.ymgme.2019.02.004 30850267 38. Patterson M.C. Garver W.S. Giugliani R. Imrie J. Jahnova H. Meaney F.J. Nadjar Y. Vanier M.T. Moneuse P. Morand O. Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study J. Inherit. Metab. Dis. 2020 43 1060 1069 10.1002/jimd.12245 32324281 39. Spiegel R. Raas-Rothschild A. Reish O. Regev M. Meiner V. Bargal R. Sury V. Meir K. Nadjari M. Hermann G. The clinical spectrum of fetal Niemann-Pick type C Am. J. Med. Genet. A 2009 149 446 450 10.1002/ajmg.a.32642 40. Jahnova H. Dvorakova L. Vlaskova H. Hulkova H. Poupetova H. Hrebicek M. Jesina P. Observational, retrospective study of a large cohort of patients with Niemann-Pick disease type C in the Czech Republic: A surprisingly stable diagnostic rate spanning almost 40 years Orphanet J. Rare Dis. 2014 9 140 10.1186/s13023-014-0140-6 25236789 41. Imrie J. Heptinstall L. Knight S. Strong K. Observational cohort study of the natural history of Niemann-Pick disease type C in the UK: A 5-year update from the UK clinical database BMC. Neurol. 2015 15 257 10.1186/s12883-015-0511-1 26666848 42. Gumus E. Haliloglu G. Karhan A.N. Demir H. Gurakan F. Topcu M. Yuce A. Niemann-Pick disease type C in the newborn period: A single-center experience Eur. J. Pediatric 2017 176 1669 1676 10.1007/s00431-017-3020-y 28951965 43. Staretz-Chacham O. Aviram M. Morag I. Goldbart A. Hershkovitz E. Pulmonary involvement in Niemann-Pick C type 1 Eur. J. Pediatric 2018 177 1609 1615 10.1007/s00431-018-3219-6 30066180 44. Pineda M. Juríčková K. Karimzadeh P. Kolnikova M. Malinova V. Insua J.L. Velten C. Kolb S.A. Disease characteristics, prognosis and miglustat treatment effects on disease progression in patients with Niemann-Pick disease Type C: An international, multicenter, retrospective chart review Orphanet J. Rare Dis. 2019 14 32 10.1186/s13023-019-0996-6 30732631 45. Yilmaz B.S. Baruteau J. Rahim A.A. Gissen P. Clinical and Molecular Features of Early Infantile Niemann Pick Type C Disease Int. J. Mol. Sci. 2020 21 5059 10.3390/ijms21145059 46. Di Lazzaro V. Marano M. Florio L. De Santis S. Niemann-Pick type C: Focus on the adolescent/adult onset form Int. J. Neurosci. 2016 126 963 971 10.3109/00207454.2016.1161623 26998855 47. Wassif C.A. Cross J.L. Iben J. Sanchez-Pulido L. Cougnoux A. Platt F.M. Ory D.S. Ponting C.P. Bailey-Wilson J.E. Biesecker L.G. High incidence of unrecognized visceral/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets Genet. Med. 2016 18 41 48 10.1038/gim.2015.25 25764212 48. Bonnot O. Klünemann H.H. Velten C. Torres Martin J.V. Walterfang M. Systematic review of psychiatric signs in Niemann-Pick disease type C World J. Biol. Psychiatry 2019 20 320 332 10.1080/15622975.2018.1441548 29457916 49. Nadjar Y. Hütter-Moncada A.L. Latour P. Ayrignac X. Kaphan E. Tranchant C. Cintas P. Degardin A. Goizet C. Laurencin C. Adult Niemann-Pick disease type C in France: Clinical phenotypes and long-term miglustat treatment effect Orphanet J. Rare Dis. 2018 13 175 10.1186/s13023-018-0913-4 30285904 50. Rego T. Farrand S. Goh A.M.Y. Eratne D. Kelso W. Mangelsdorf S. Velakoulis D. Walterfang M. Psychiatric and Cognitive Symptoms Associated with Niemann-Pick Type C Disease: Neurobiology and Management CNS Drugs 2019 33 125 142 10.1007/s40263-018-0599-0 30632019 51. Porter F.D. Scherrer D.E. Lanier M.H. Langmade S.J. Molugu V. Gale S.E. Olzeski D. Sidhu R. Dietzen D.J. Fu R. Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease Sci. Transl. Med. 2010 2 56ra81 10.1126/scitranslmed.3001417 21048217 52. Giese A.K. Mascher H. Grittner U. Eichler S. Kramp G. Lukas J. Te Vruchte D. Al Eisa N. Cortina-Borja M. Porter F.D. A novel, highly sensitive and specific biomarker for Niemann-Pick type C1 disease Orphanet J. Rare Dis. 2015 10 78 10.1186/s13023-015-0274-1 26082315 53. Jiang X. Sidhu R. Mydock-McGrane L. Hsu F.F. Covey D.F. Scherrer D.E. Earley B. Gale S.E. Farhat N.Y. Porter F.D. Development of a bile acid-based newborn screen for Niemann-Pick disease type C Sci. Transl. Med. 2016 8 337ra363 10.1126/scitranslmed.aaf2326 54. Maekawa M. Jinnoh I. Matsumoto Y. Narita A. Mashima R. Takahashi H. Iwahori A. Saigusa D. Fujii K. Abe A. Structural Determination of Lysosphingomyelin-509 and Discovery of Novel Class Lipids from Patients with Niemann-Pick Disease Type C Int. J. Mol. Sci. 2019 20 5018 10.3390/ijms20205018 55. Sidhu R. Kell P. Dietzen D.J. Farhat N.Y. Do A.N.D. Porter F.D. Berry-Kravis E. Vite C.H. Reunert J. Marquardt T. Application of N-palmitoyl-O-phosphocholineserine for diagnosis and assessment of response to treatment in Niemann-Pick type C disease Mol. Genet. Metab. 2020 129 292 302 10.1016/j.ymgme.2020.01.007 32033912 56. Vanier M.T. Gissen P. Bauer P. Coll M.J. Burlina A. Hendriksz C.J. Latour P. Goizet C. Welford R.W. Marquardt T. Diagnostic tests for Niemann-Pick disease type C (NP-C): A critical review Mol. Genet. Metab. 2016 118 244 254 10.1016/j.ymgme.2016.06.004 27339554 57. Patterson M.C. Clayton P. Gissen P. Anheim M. Bauer P. Bonnot O. Dardis A. Dionisi-Vici C. Klünemann H.H. Latour P. Recommendations for the detection and diagnosis of Niemann-Pick disease type C: An update Neurol. Clin. Pract. 2017 7 499 511 10.1212/CPJ.0000000000000399 29431164 58. Sitarska D. Ługowska A. Laboratory diagnosis of the Niemann-Pick type C disease: An inherited neurodegenerative disorder of cholesterol metabolism Metab. Brain Dis. 2019 34 1253 1260 10.1007/s11011-019-00445-w 31197681 59. Vanier M.T. Latour P. Laboratory diagnosis of Niemann-Pick disease type C: The filipin staining test Methods Cell Biol. 2015 126 357 375 25665455 60. Patterson M.C. Vecchio D. Prady H. Abel L. Wraith J.E. Miglustat for treatment of Niemann-Pick C disease: A randomised controlled study Lancet Neurol. 2007 6 765 772 10.1016/S1474-4422(07)70194-1 17689147 61. Pineda M. Walterfang M. Patterson M.C. Miglustat in Niemann-Pick disease type C patients: A review Orphanet J. Rare Dis. 2018 13 140 10.1186/s13023-018-0844-0 30111334 62. Stirnemann J. Belmatoug N. Camou F. Serratrice C. Froissart R. Caillaud C. Levade T. Astudillo L. Serratrice J. Brassier A. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments Int. J. Mol. Sci. 2017 18 441 10.3390/ijms18020441 63. Platt F.M. Emptying the stores: Lysosomal diseases and therapeutic strategies Nat. Rev. Drug Discov. 2018 17 133 150 10.1038/nrd.2017.214 29147032 64. Harvey W. Leake C.D. Exercitatio anatomica de motu cordis et sanguinis in animalibus Am. J. Med. Sci. 1929 177 578 10.1097/00000441-192904000-00020 65. Descartes R. Discours de la Methode Pour Bien Conduire la Raison et Chercher la Verité Dans les Sciences De l’imprimérie de Ian Maire Ian Maire, Leyden 1637 66. Bentham J. An Introduction to the Principles of Morals and Legislation T. Payne and Sons London, UK 1789 67. Russell W.M.S.B. The Principles of Humane Experimental Technique Universities Federation for Animal Welfare Wheathampstead, UK 1959 68. Tannenbaum J. Bennett B.T. Russell and Burch’s 3Rs then and now: The need for clarity in definition and purpose J. Am. Assoc. Lab. Anim. Sci. 2015 54 120 132 25836957 69. Flanagan S.P. ‘Nude’, a new hairless gene with pleiotropic effects in the mouse Genet. Res. 1966 8 295 309 10.1017/S0016672300010168 5980117 70. Lai Y. Wei X. Lin S. Qin L. Cheng L. Li P. Current status and perspectives of patient-derived xenograft models in cancer research J. Hematol. Oncol. 2017 10 106 10.1186/s13045-017-0470-7 28499452 71. Arison R.N. Ciaccio E.I. Glitzer M.S. Cassaro J.A. Pruss M.P. Light and Electron Microscopy of Lesions in Rats Rendered Diabetic with Streptozotocin Diabetes 1967 16 51 56 10.2337/diab.16.1.51 6015682 72. Lazarus S.S. Shapiro S.H. Serial morphologic changes in rabbit pancreatic islet cells after streptozotocin Lab. Investig. 1972 27 174 183 4262393 73. Burns R.S. Chiueh C.C. Markey S.P. Ebert M.H. Jacobowitz D.M. Kopin I.J. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Proc. Natl. Acad. Sci. USA 1983 80 4546 4550 10.1073/pnas.80.14.4546 6192438 74. Servadio M. Vanderschuren L.J. Trezza V. Modeling autism-relevant behavioral phenotypes in rats and mice Behav. Pharmacol. 2015 26 522 540 10.1097/FBP.0000000000000163 26226143 75. Lunardi Baccetto S. Lehmann C. Microcirculatory Changes in Experimental Models of Stroke and CNS-Injury Induced Immunodepression Int. J. Mol. Sci. 2019 20 5184 10.3390/ijms20205184 31635068 76. Wagner L. Pannicke T. Rupprecht V. Frommherz I. Volz C. Illes P. Hirrlinger J. Jägle H. Egger V. Haydon P.G. Suppression of SNARE-dependent exocytosis in retinal glial cells and its effect on ischemia-induced neurodegeneration Glia 2017 65 1059 1071 10.1002/glia.23144 28370368 77. Karamian P. Burford J. Farzad S. Blair N.P. Shahidi M. Alterations in Retinal Oxygen Delivery, Metabolism, and Extraction Fraction During Bilateral Common Carotid Artery Occlusion in Rats Investig. Ophthalmol. Vis. Sci. 2019 60 3247 3253 10.1167/iovs.19-27227 31343655 78. Fiorentino S. Melillo G. Fedele G. Clavenna G. D’Agostino C. Mainetti E. Caselli G.F. Ketoprofen lysine salt inhibits disuse-induced osteopenia in a new non-traumatic immobilization model in the rat Pharmacol. Res. 1996 33 277 281 10.1006/phrs.1996.0039 8938021 79. Hanahan D. Wagner E.F. Palmiter R.D. The origins of oncomice: A history of the first transgenic mice genetically engineered to develop cancer Genes Dev. 2007 21 2258 2270 10.1101/gad.1583307 17875663 80. Cooper J.F. Van Raamsdonk J.M. Modeling Parkinson’s Disease in C. elegans J. Park. Dis. 2018 8 17 32 10.3233/JPD-171258 81. Fang E.F. Hou Y. Palikaras K. Adriaanse B.A. Kerr J.S. Yang B. Lautrup S. Hasan-Olive M.M. Caponio D. Dan X. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease Nat. Neurosci. 2019 22 401 412 10.1038/s41593-018-0332-9 30742114 82. Morley J.F. Brignull H.R. Weyers J.J. Morimoto R.I. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans Proc. Natl. Acad. Sci. USA 2002 99 10417 10422 10.1073/pnas.152161099 12122205 83. de Voer G. Peters D. Taschner P.E. Caenorhabditis elegans as a model for lysosomal storage disorders Biochim. Biophys. Acta 2008 1782 433 446 10.1016/j.bbadis.2008.04.003 18501720 84. Jeibmann A. Paulus W. Drosophila melanogaster as a Model Organism of Brain Diseases Int. J. Mol. Sci. 2009 10 407 440 10.3390/ijms10020407 19333415 85. Prüßing K. Voigt A. Schulz J.B. Drosophila melanogaster as a model organism for Alzheimer’s disease Mol. Neurodegener. 2013 8 35 10.1186/1750-1326-8-35 24267573 86. Smith P. Arias R. Sonti S. Odgerel Z. Santa-Maria I. McCabe B.D. Tsaneva-Atanasova K. Louis E.D. Hodge J.J.L. Clark L.N. A Drosophila Model of Essential Tremor Sci. Rep. 2018 8 7664 10.1038/s41598-018-25949-w 29769701 87. Rodan A.R. The Drosophila Malpighian tubule as a model for mammalian tubule function Curr. Opin. Nephrol. Hypertens. 2019 28 455 464 10.1097/MNH.0000000000000521 31268918 88. Schultz S.W. Nilsson K.P. Westermark G.T. Drosophila melanogaster as a model system for studies of islet amyloid polypeptide aggregation PLoS ONE 2011 6 e20221 10.1371/journal.pone.0020221 21695120 89. Mann R.D. Modern Drug Use: An Enquiry on Historical Principles MTP Press Lancaster, UK 1984 769 90. King N.W. Simian Models of Acquired Immunodeficiency Syndrome (AIDS): A Review Vet. Pathol. 1986 23 345 353 10.1177/030098588602300401 3529592 91. Yamawaki I. Geppetti P. Bertrand C. Huber O. Daffonchio L. Omini C. Nadel J.A. Levodropropizine reduces capsaicin- and substance P-induced plasma extravasation in the rat trachea Eur. J. Pharmacol. 1993 243 1 6 10.1016/0014-2999(93)90159-F 7504629 92. Luo Y.L. Li P.B. Zhang C.C. Zheng Y.F. Wang S. Nie Y.C. Zhang K.J. Su W.W. Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure Inflamm. Res. 2013 62 1053 1061 10.1007/s00011-013-0664-6 24085318 93. Banderali G. Riva E. Fiocchi A. Cordaro C.I. Giovannini M. Efficacy and tolerability of levodropropizine and dropropizine in children with non-productive cough J. Int. Med. Res. 1995 23 175 183 10.1177/030006059502300304 7649341 94. Bolser D.C. Experimental models and mechanisms of enhanced coughing Pulm. Pharmacol. Ther. 2004 17 383 388 10.1016/j.pupt.2004.09.016 15564080 95. Rosen B.H. Chanson M. Gawenis L.R. Liu J. Sofoluwe A. Zoso A. Engelhardt J.F. Animal and model systems for studying cystic fibrosis J. Cyst. Fibros. 2018 17 S28 S34 10.1016/j.jcf.2017.09.001 28939349 96. Hastings J.M. Fazleabas A.T. A baboon model for endometriosis: Implications for fertility Reprod. Biol. Endocrinol. 2006 4 S7 10.1186/1477-7827-4-S1-S7 17118171 97. Balamayooran G. Pena M. Sharma R. Truman R.W. The armadillo as an animal model and reservoir host for Mycobacterium leprae Clin. Dermatol. 2015 33 108 115 10.1016/j.clindermatol.2014.07.001 25432816 98. Milton S.L. Prentice H.M. Beyond anoxia: The physiology of metabolic downregulation and recovery in the anoxia-tolerant turtle Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2007 147 277 290 10.1016/j.cbpa.2006.08.041 17049896 99. Trevino M. Lobarinas E. Maulden A.C. Heinz M.G. The chinchilla animal model for hearing science and noise-induced hearing loss J. Acoust. Soc. Am. 2019 146 3710 10.1121/1.5132950 31795699 100. Verra D.M. Sajdak B.S. Merriman D.K. Hicks D. Diurnal rodents as pertinent animal models of human retinal physiology and pathology Prog. Retin. Eye Res. 2020 74 100776 10.1016/j.preteyeres.2019.100776 31499165 101. Yamanaka S. Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges Cell Stem. Cell 2020 27 523 531 10.1016/j.stem.2020.09.014 33007237 102. Sellgren C.M. Gracias J. Watmuff B. Biag J.D. Thanos J.M. Whittredge P.B. Fu T. Worringer K. Brown H.E. Wang J. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning Nat. Neurosci. 2019 22 374 385 10.1038/s41593-018-0334-7 30718903 103. Fog C.K. Kirkegaard T. Animal models for Niemann-Pick type C: Implications for drug discovery & development Expert Opin. Drug Discov. 2019 14 499 509 30887840 104. Higaki K. Almanzar-Paramio D. Sturley S.L. Metazoan and microbial models of Niemann-Pick Type C disease Biochim. Biophys. Acta 2004 1685 38 47 10.1016/j.bbalip.2004.08.010 15465425 105. Feldman M.J. Poirier B.C. Lange B.M. Misexpression of the Niemann-Pick disease type C1 (NPC1)-like protein in Arabidopsis causes sphingolipid accumulation and reproductive defects Planta 2015 242 921 933 10.1007/s00425-015-2322-4 26007685 106. Malathi K. Higaki K. Tinkelenberg A.H. Balderes D.A. Almanzar-Paramio D. Wilcox L.J. Erdeniz N. Redican F. Padamsee M. Liu Y. Mutagenesis of the putative sterol-sensing domain of yeast Niemann Pick C-related protein reveals a primordial role in subcellular sphingolipid distribution J. Cell Biol. 2004 164 547 556 10.1083/jcb.200310046 14970192 107. Zhu J. Wang G. Pelosi P. Plant transcriptomes reveal hidden guests Biochem. Biophys. Res. Commun. 2016 474 497 502 10.1016/j.bbrc.2016.04.134 27130825 108. Berger A.C. Vanderford T.H. Gernert K.M. Nichols J.W. Faundez V. Corbett A.H. Saccharomyces cerevisiae Npc2p is a functionally conserved homologue of the human Niemann-Pick disease type C 2 protein, hNPC2 Eukaryot. Cell 2005 4 1851 1862 10.1128/EC.4.11.1851-1862.2005 16278452 109. Munkacsi A.B. Chen F.W. Brinkman M.A. Higaki K. Gutiérrez G.D. Chaudhari J. Layer J.V. Tong A. Bard M. Boone C. An “exacerbate-reverse” strategy in yeast identifies histone deacetylase inhibition as a correction for cholesterol and sphingolipid transport defects in human Niemann-Pick type C disease J. Biol. Chem. 2011 286 23842 23851 10.1074/jbc.M111.227645 21489983 110. Tsuji T. Fujimoto M. Tatematsu T. Cheng J. Orii M. Takatori S. Fujimoto T. Niemann-Pick type C proteins promote microautophagy by expanding raft-like membrane domains in the yeast vacuole eLife 2017 6 e25960 10.7554/eLife.25960 28590904 111. Colaco A. Fernández-Suárez M.E. Shepherd D. Gal L. Bibi C. Chuartzman S. Diot A. Morten K. Eden E. Porter F.D. Unbiased yeast screens identify cellular pathways affected in Niemann-Pick disease type C Life Sci. Alliance 2020 3 e201800253 10.26508/lsa.201800253 32487688 112. Bolaños J. Betanzos A. Javier-Reyna R. García-Rivera G. Huerta M. Pais-Morales J. González-Robles A. Rodríguez M.A. Schnoor M. Orozco E. EhNPC1 and EhNPC2 Proteins Participate in Trafficking of Exogenous Cholesterol in Entamoeba histolytica Trophozoites: Relevance for Phagocytosis PLoS Pathog. 2016 12 e1006089 10.1371/journal.ppat.1006089 28002502 113. Sym M. Basson M. Johnson C. A model for Niemann–Pick type C disease in the nematode Caenorhabditis elegans Curr. Biol. 2000 10 527 530 10.1016/S0960-9822(00)00468-1 10801441 114. Li J. Brown G. Ailion M. Lee S. Thomas J.H. NCR-1 and NCR-2, the C. elegans homologs of the human Niemann-Pick type C1 disease protein, function upstream of DAF-9 in the dauer formation pathways Development 2004 131 5741 5752 10.1242/dev.01408 15509773 115. Wüstner D. Landt Larsen A. Faergeman N.J. Brewer J.R. Sage D. Selective visualization of fluorescent sterols in Caenorhabditis elegans by bleach-rate-based image segmentation Traffic 2010 11 440 454 10.1111/j.1600-0854.2010.01040.x 20070610 116. Smith M.M. Levitan D.J. Human NPC1L1 and NPC1 can functionally substitute for the ncr genes to promote reproductive development in C. elegans Biochim. Biophys. Acta 2007 1770 1345 1351 10.1016/j.bbagen.2007.06.004 17662536 117. Boland S. Schmidt U. Zagoriy V. Sampaio J.L. Fritsche R.F. Czerwonka R. Lübken T. Reimann J. Penkov S. Knölker H.J. Phosphorylated glycosphingolipids essential for cholesterol mobilization in Caenorhabditis elegans Nat. Chem. Biol. 2017 13 647 654 10.1038/nchembio.2347 28369040 118. Galles C. Prez G.M. Penkov S. Boland S. Porta E.O.J. Altabe S.G. Labadie G.R. Schmidt U. Knölker H.J. Kurzchalia T.V. Endocannabinoids in Caenorhabditis elegans are essential for the mobilization of cholesterol from internal reserves Sci. Rep. 2018 8 6398 10.1038/s41598-018-24925-8 29686301 119. Huang X. Suyama K. Buchanan J. Zhu A.J. Scott M.P. A Drosophila model of the Niemann-Pick type C lysosome storage disease: Dnpc1a is required for molting and sterol homeostasis Development 2005 132 5115 5124 10.1242/dev.02079 16221727 120. Fluegel M.L. Parker T.J. Pallanck L.J. Mutations of a Drosophila NPC1 gene confer sterol and ecdysone metabolic defects Genetics 2006 172 185 196 10.1534/genetics.105.046565 16079224 121. Voght S.P. Fluegel M.L. Andrews L.A. Pallanck L.J. Drosophila NPC1b promotes an early step in sterol absorption from the midgut epithelium Cell Metab. 2007 5 195 205 10.1016/j.cmet.2007.01.011 17339027 122. Huang X. Warren J.T. Buchanan J. Gilbert L.I. Scott M.P. Drosophila Niemann-Pick Type C-2 genes control sterol homeostasis and steroid biosynthesis: A model of human neurodegenerative disease Development 2007 134 3733 3742 10.1242/dev.004572 17804599 123. Phillips S.E. Woodruff E.A. III Liang P. Patten M. Broadie K. Neuronal loss of Drosophila NPC1a causes cholesterol aggregation and age-progressive neurodegeneration J. Neurosci. 2008 28 6569 6582 10.1523/JNEUROSCI.5529-07.2008 18579730 124. Danielsen E.T. Moeller M.E. Yamanaka N. Ou Q. Laursen J.M. Soenderholm C. Zhuo R. Phelps B. Tang K. Zeng J. A Drosophila Genome-Wide Screen Identifies Regulators of Steroid Hormone Production and Developmental Timing Dev. Cell 2016 37 558 570 10.1016/j.devcel.2016.05.015 27326933 125. Schwend T. Loucks E.J. Snyder D. Ahlgren S.C. Requirement of Npc1 and availability of cholesterol for early embryonic cell movements in zebrafish J. Lipid Res. 2011 52 1328 1344 10.1194/jlr.M012377 21576600 126. Louwette S. Régal L. Wittevrongel C. Thys C. Vandeweeghde G. Decuyper E. Leemans P. De Vos R. Van Geet C. Jaeken J. NPC1 defect results in abnormal platelet formation and function: Studies in Niemann-Pick disease type C1 patients and zebrafish Hum. Mol. Genet. 2013 22 61 73 10.1093/hmg/dds401 23010472 127. Lin Y. Cai X. Wang G. Ouyang G. Cao H. Model construction of Niemann-Pick type C disease in zebrafish Biol. Chem. 2018 399 903 910 10.1515/hsz-2018-0118 29897878 128. Tseng W.-C. Loeb H.E. Pei W. Tsai-Morris C.-H. Xu L. Cluzeau C.V. Wassif C.A. Feldman B. Burgess S.M. Pavan W.J. Modeling Niemann-Pick disease type C1 in zebrafish: A robust platform for in vivo screening of candidate therapeutic compounds Dis. Model. Mech. 2018 11 dmm034165 10.1242/dmm.034165 30135069 129. Pentchev P.G. Gal A.E. Booth A.D. Omodeo-Sale F. Fours J. Neumeyer B.A. Quirk J.M. Dawson G. Brady R.O. A lysosomal storage disorder in mice characterized by a dual deficiency of sphingomyelinase and glucocerebrosidase Biochim. Biophys. Acta 1980 619 669 679 10.1016/0005-2760(80)90116-2 6257302 130. Miyawaki S. Mitsuoka S. Sakiyama T. Kitagawa T. Sphingomyelinosis, a new mutation in the mouse: A model of Niemann-Pick disease in humans J. Hered. 1982 73 257 263 10.1093/oxfordjournals.jhered.a109635 7202025 131. Xie X. Brown M.S. Shelton J.M. Richardson J.A. Goldstein J.L. Liang G. Amino acid substitution in NPC1 that abolishes cholesterol binding reproduces phenotype of complete NPC1 deficiency in mice Proc. Natl. Acad. Sci. USA 2011 108 15330 15335 10.1073/pnas.1112751108 21896731 132. Maue R.A. Burgess R.W. Wang B. Wooley C.M. Seburn K.L. Vanier M.T. Rogers M.A. Chang C.C. Chang T.Y. Harris B.T. A novel mouse model of Niemann-Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutations Hum. Mol. Genet. 2012 21 730 750 10.1093/hmg/ddr505 22048958 133. Praggastis M. Tortelli B. Zhang J. Fujiwara H. Sidhu R. Chacko A. Chen Z. Chung C. Lieberman A.P. Sikora J. A murine Niemann-Pick C1 I1061T knock-in model recapitulates the pathological features of the most prevalent human disease allele J. Neurosci. 2015 35 8091 8106 10.1523/JNEUROSCI.4173-14.2015 26019327 134. Gómez-Grau M. Albaigès J. Casas J. Auladell C. Dierssen M. Vilageliu L. Grinberg D. New murine Niemann-Pick type C models bearing a pseudoexon-generating mutation recapitulate the main neurobehavioural and molecular features of the disease Sci. Rep. 2017 7 41931 10.1038/srep41931 28167839 135. Rodriguez-Gil J.L. Watkins-Chow D.E. Baxter L.L. Elliot G. Harper U.L. Wincovitch S.M. Wedel J.C. Incao A.A. Huebecker M. Boehm F. Genetic background modifies phenotypic severity and longevity in a mouse model of Niemann-Pick disease type C1 Dis. Model. Mech. 2020 13 dmm042614 10.1242/dmm.042614 31996359 136. Elrick M.J. Pacheco C.D. Yu T. Dadgar N. Shakkottai V.G. Ware C. Paulson H.L. Lieberman A.P. Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration Hum. Mol. Genet. 2010 19 837 847 10.1093/hmg/ddp552 20007718 137. Rimkunas V.M. Graham M.J. Crooke R.M. Liscum L. In vivo antisense oligonucleotide reduction of NPC1 expression as a novel mouse model for Niemann Pick type C-associated liver disease Hepatology 2008 47 1504 1512 10.1002/hep.22327 18438776 138. Zhang M. Strnatka D. Donohue C. Hallows J.L. Vincent I. Erickson R.P. Astrocyte-only Npc1 reduces neuronal cholesterol and triples life span of Npc1-/- mice J. Neurosci. Res. 2008 86 2848 2856 10.1002/jnr.21730 18500759 139. Lopez M.E. Klein A.D. Dimbil U.J. Scott M.P. Anatomically defined neuron-based rescue of neurodegenerative Niemann-Pick type C disorder J. Neurosci. 2011 31 4367 4378 10.1523/JNEUROSCI.5981-10.2011 21430138 140. Bosch M. Fajardo A. Alcalá-Vida R. Fernández-Vidal A. Tebar F. Enrich C. Cardellach F. Pérez-Navarro E. Pol A. Hepatic Primary and Secondary Cholesterol Deposition and Damage in Niemann-Pick Disease Am. J. Pathol. 2016 186 517 523 10.1016/j.ajpath.2015.12.002 26784526 141. Lowenthal A.C. Cummings J.F. Wenger D.A. Thrall M.A. Wood P.A. de Lahunta A. Feline sphingolipidosis resembling Niemann-Pick disease type C Acta Neuropathol. 1990 81 189 197 10.1007/BF00334507 2127982 142. Muñana K.R. Luttgen P.J. Thrall M.A. Mitchell T.W. Wenger D.A. Neurological manifestations of Niemann-Pick disease type C in cats J. Vet. Intern. Med. 1994 8 117 121 10.1111/j.1939-1676.1994.tb03208.x 8046674 143. Somers K.L. Royals M.A. Carstea E.D. Rafi M.A. Wenger D.A. Thrall M.A. Mutation analysis of feline Niemann-Pick C1 disease Mol. Genet. Metab. 2003 79 99 103 10.1016/S1096-7192(03)00074-X 12809639 144. Woolley S.A. Tsimnadis E.R. Lenghaus C. Healy P.J. Walker K. Morton A. Khatkar M.S. Elliott A. Kaya E. Hoerner C. Molecular basis for a new bovine model of Niemann-Pick type C disease PLoS ONE 2020 15 e0238697 10.1371/journal.pone.0238697 32970694 145. Sleat D.E. Wiseman J.A. El-Banna M. Price S.M. Verot L. Shen M.M. Tint G.S. Vanier M.T. Walkley S.U. Lobel P. Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport Proc. Natl. Acad. Sci. USA 2004 101 5886 5891 10.1073/pnas.0308456101 15071184 146. Schrantz N. Sagiv Y. Liu Y. Savage P.B. Bendelac A. Teyton L. The Niemann-Pick type C2 protein loads isoglobotrihexosylceramide onto CD1d molecules and contributes to the thymic selection of NKT cells J. Exp. Med. 2007 204 841 852 10.1084/jem.20061562 17389239 147. Nielsen G.K. Dagnaes-Hansen F. Holm I.E. Meaney S. Symula D. Andersen N.T. Heegaard C.W. Protein Replacement Therapy Partially Corrects the Cholesterol-Storage Phenotype in a Mouse Model of Niemann-Pick Type C2 Disease PLoS ONE 2011 6 e27287 10.1371/journal.pone.0027287 22073306 148. Acuña M. González-Hódar L. Amigo L. Castro J. Morales M.G. Cancino G.I. Groen A.K. Young J. Miquel J.F. Zanlungo S. Transgenic overexpression of Niemann-Pick C2 protein promotes cholesterol gallstone formation in mice J. Hepatol. 2016 64 361 369 10.1016/j.jhep.2015.10.002 26453970 149. Kuwamura M. Awakura T. Shimada A. Umemura T. Kagota K. Kawamura N. Naiki M. Type C Niemann-Pick disease in a boxer dog Acta Neuropathol. 1993 85 345 348 10.1007/BF00227733 8460536 150. Zervas M. Dobrenis K. Walkley S.U. Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations J. Neuropathol. Exp. Neurol. 2001 60 49 64 10.1093/jnen/60.1.49 11202175 151. Reid P.C. Sakashita N. Sugii S. Ohno-Iwashita Y. Shimada Y. Hickey W.F. Chang T.Y. A novel cholesterol stain reveals early neuronal cholesterol accumulation in the Niemann-Pick type C1 mouse brain J. Lipid Res. 2004 45 582 591 10.1194/jlr.D300032-JLR200 14703504 152. Beltroy E.P. Richardson J.A. Horton J.D. Turley S.D. Dietschy J.M. Cholesterol accumulation and liver cell death in mice with Niemann-Pick type C disease Hepatology 2005 42 886 893 10.1002/hep.20868 16175610 153. Li H. Repa J.J. Valasek M.A. Beltroy E.P. Turley S.D. German D.C. Dietschy J.M. Molecular, anatomical, and biochemical events associated with neurodegeneration in mice with Niemann-Pick type C disease J. Neuropathol. Exp. Neurol. 2005 64 323 333 10.1093/jnen/64.4.323 15835268 154. Claudepierre T. Paques M. Simonutti M. Buard I. Sahel J. Maue R.A. Picaud S. Pfrieger F.W. Lack of Niemann Pick type C1 induces age-related degeneration in the mouse retina Mol. Cell Neurosci. 2010 43 164 176 10.1016/j.mcn.2009.10.007 19883762 155. Tanaka J. Nakamura H. Miyawaki S. Cerebellar involvement in murine sphingomyelinosis: A new model of Niemann-Pick disease J. Neuropathol. Exp. Neurol. 1988 47 291 300 10.1097/00005072-198805000-00008 3130465 156. Higashi Y. Murayama S. Pentchev P.G. Suzuki K. Cerebellar degeneration in the Niemann-Pick type C mouse Acta Neuropathol. 1993 85 175 184 10.1007/BF00227765 8382896 157. Sarna J.R. Larouche M. Marzban H. Sillitoe R.V. Rancourt D.E. Hawkes R. Patterned Purkinje cell degeneration in mouse models of Niemann-Pick type C disease J. Comp. Neurol. 2003 456 279 291 10.1002/cne.10522 12528192 158. Ko D.C. Milenkovic L. Beier S.M. Manuel H. Buchanan J. Scott M.P. Cell-autonomous death of cerebellar purkinje neurons with autophagy in Niemann-Pick type C disease PLoS. Genet. 2005 1 81 95 16103921 159. Liao G. Yao Y. Liu J. Yu Z. Cheung S. Xie A. Liang X. Bi X. Cholesterol accumulation is associated with lysosomal dysfunction and autophagic stress in Npc1 -/- mouse brain Am. J. Pathol. 2007 171 962 975 10.2353/ajpath.2007.070052 17631520 160. Pacheco C.D. Kunkel R. Lieberman A.P. Autophagy in Niemann-Pick C disease is dependent upon Beclin-1 and responsive to lipid trafficking defects Hum. Mol. Genet. 2007 16 1495 1503 10.1093/hmg/ddm100 17468177 161. Burns M. Gaynor K. Olm V. Mercken M. LaFrancois J. Wang L. Mathews P.M. Noble W. Matsuoka Y. Duff K. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo J. Neurosci. 2003 23 5645 5649 10.1523/JNEUROSCI.23-13-05645.2003 12843267 162. Erickson R.P. Garver W.S. Camargo F. Hossain G.S. Heidenreich R.A. Pharmacological and genetic modifications of somatic cholesterol do not substantially alter the course of CNS disease in Niemann-Pick C mice J. Inherit. Metab. Dis 2000 23 54 62 10.1023/A:1005650930330 10682308 163. Erickson R.P. Bernard O. Studies on neuronal death in the mouse model of Niemann-Pick C disease J. Neurosci. Res. 2002 68 738 744 10.1002/jnr.10257 12111834 164. Zhang M. Hallows J.L. Wang X. Bu B. Wang W. Vincent I. Mitogen-activated protein kinase activity may not be necessary for the neuropathology of Niemann-Pick type C mice J. Neurochem. 2008 107 814 822 10.1111/j.1471-4159.2008.05657.x 18778306 165. Somers K.L. Brown D.E. Fulton R. Schultheiss P.C. Hamar D. Smith M.O. Allison R. Connally H.E. Just C. Mitchell T.W. Effects of dietary cholesterol restriction in a feline model of Niemann-Pick type C disease J. Inherit. Metab. Dis. 2001 24 427 436 10.1023/A:1010588112003 11596647 166. Ahmad I. Hunter R.E. Flax J.D. Snyder E.Y. Erickson R.P. Neural stem cell implantation extends life in Niemann-Pick C1 mice J. Appl Genet. 2007 48 269 272 10.1007/BF03195222 17666780 167. Bae J.S. Han H.S. Youn D.H. Carter J.E. Modo M. Schuchman E.H. Jin H.K. Bone marrow-derived mesenchymal stem cells promote neuronal networks with functional synaptic transmission after transplantation into mice with neurodegeneration Stem. Cells 2007 25 1307 1316 10.1634/stemcells.2006-0561 17470534 168. Lee H. Bae J.S. Jin H.K. Human umbilical cord blood-derived mesenchymal stem cells improve neurological abnormalities of Niemann-Pick type C mouse by modulation of neuroinflammatory condition J. Vet. Med. Sci. 2010 72 709 717 10.1292/jvms.09-0495 20124762 169. Bae J.S. Carter J.E. Jin H.K. Adipose tissue-derived stem cells rescue Purkinje neurons and alleviate inflammatory responses in Niemann-Pick disease type C mice Cell Tissue Res. 2010 340 357 369 10.1007/s00441-010-0942-3 20238127 170. Smith D. Wallom K.L. Williams I.M. Jeyakumar M. Platt F.M. Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1 Neurobiol. Dis. 2009 36 242 251 10.1016/j.nbd.2009.07.010 19632328 171. Bascuñan-Castillo E.C. Erickson R.P. Howison C.M. Hunter R.J. Heidenreich R.H. Hicks C. Trouard T.P. Gillies R.J. Tamoxifen and vitamin E treatments delay symptoms in the mouse model of Niemann-Pick C J. Appl. Genet. 2004 45 461 467 15523158 172. Marín T. Contreras P. Castro J.F. Chamorro D. Balboa E. Bosch-Morató M. Muñoz F.J. Alvarez A.R. Zanlungo S. Vitamin E dietary supplementation improves neurological symptoms and decreases c-Abl/p73 activation in Niemann-Pick C mice Nutrients 2014 6 3000 3017 10.3390/nu6083000 25079853 173. Repa J.J. Li H. Frank-Cannon T.C. Valasek M.A. Turley S.D. Tansey M.G. Dietschy J.M. Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse J. Neurosci. 2007 27 14470 14480 10.1523/JNEUROSCI.4823-07.2007 18160655 174. Langmade S.J. Gale S.E. Frolov A. Mohri I. Suzuki K. Mellon S.H. Walkley S.U. Covey D.F. Schaffer J.E. Ory D.S. Pregnane X receptor (PXR) activation: A mechanism for neuroprotection in a mouse model of Niemann-Pick C disease Proc. Natl. Acad. Sci. USA 2006 103 13807 13812 10.1073/pnas.0606218103 16940355 175. Chen G. Li H.M. Chen Y.R. Gu X.S. Duan S. Decreased estradiol release from astrocytes contributes to the neurodegeneration in a mouse model of Niemann-Pick disease type C GLIA 2007 55 1509 1518 10.1002/glia.20563 17705200 176. Alvarez A.R. Klein A. Castro J. Cancino G.I. Amigo J. Mosqueira M. Vargas L.M. Yévenes L.F. Bronfman F.C. Zanlungo S. Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease FASEB J. 2008 22 3617 3627 10.1096/fj.07-102715 18591368 177. Liu B. Li H. Repa J.J. Turley S.D. Dietschy J.M. Genetic variations and treatments that affect the lifespan of the NPC1 mouse J. Lipid Res. 2008 49 663 669 10.1194/jlr.M700525-JLR200 18077828 178. Liu B. Turley S.D. Burns D.K. Miller A.M. Repa J.J. Dietschy J.M. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse Proc. Natl. Acad. Sci. USA 2009 106 2377 2382 10.1073/pnas.0810895106 19171898 179. Davidson C.D. Ali N.F. Micsenyi M.C. Stephney G. Renault S. Dobrenis K. Ory D.S. Vanier M.T. Walkley S.U. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression PLoS ONE 2009 4 e6951 10.1371/journal.pone.0006951 19750228 180. Aqul A. Liu B. Ramirez C.M. Pieper A.A. Estill S.J. Burns D.K. Liu B. Repa J.J. Turley S.D. Dietschy J.M. Unesterified cholesterol accumulation in late endosomes/lysosomes causes neurodegeneration and is prevented by driving cholesterol export from this compartment J. Neurosci. 2011 31 9404 9413 10.1523/JNEUROSCI.1317-11.2011 21697390 181. Vite C.H. Bagel J.H. Swain G.P. Prociuk M. Sikora T.U. Stein V.M. O’Donnell P. Ruane T. Ward S. Crooks A. Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease Sci. Transl. Med. 2015 7 276ra226 10.1126/scitranslmed.3010101 182. Hao Y. Pan D. Zhang M. Xu J. Li L. Wei J. Wang X. The neuroprotective effects of cyclin-dependent kinase-5 inhibition in mice with Niemann-Pick disease type C J. Huazhong Univ. Sci. Technolog. Med. Sci. 2009 29 324 329 10.1007/s11596-009-0312-0 19513615 183. Borbon I.A. Hillman Z. Duran E. Jr. Kiela P.R. Frautschy S.A. Erickson R.P. Lack of efficacy of curcumin on neurodegeneration in the mouse model of Niemann-Pick C1 Pharmacol. Biochem. Behav. 2012 101 125 131 10.1016/j.pbb.2011.12.009 22202649 184. Stein V.M. Crooks A. Ding W. Prociuk M. O’Donnell P. Bryan C. Sikora T. Dingemanse J. Vanier M.T. Walkley S.U. Miglustat improves purkinje cell survival and alters microglial phenotype in feline niemann-pick disease type C J. Neuropathol. Exp. Neurol. 2012 71 434 448 10.1097/NEN.0b013e31825414a6 22487861 185. Nietupski J.B. Pacheco J.J. Chuang W.L. Maratea K. Li L. Foley J. Ashe K.M. Cooper C.G. Aerts J.M. Copeland D.P. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice Mol. Genet. Metab. 2012 105 621 628 10.1016/j.ymgme.2012.01.020 22366055 186. Fu R. Wassif C.A. Yanjanin N.M. Watkins-Chow D.E. Baxter L.L. Incao A. Liscum L. Sidhu R. Firnkes S. Graham M. Efficacy of N-acetylcysteine in phenotypic suppression of mouse models of Niemann-Pick disease, type C1 Hum. Mol. Genet. 2013 22 3508 3523 10.1093/hmg/ddt206 23666527 187. Argüello G. Martinez P. Peña J. Chen O. Platt F. Zanlungo S. González M. Hepatic metabolic response to restricted copper intake in a Niemann-Pick C murine model Metallomics 2014 6 1527 1539 10.1039/C4MT00056K 24901380 188. Seo Y. Shin Y. Kim H.S. Kang I. Hong I.S. Choi S.W. Yu K.R. Kang K.S. Donepezil enhances Purkinje cell survival and alleviates motor dysfunction by inhibiting cholesterol synthesis in a murine model of Niemann Pick disease type C J. Neuropathol. Exp. Neurol. 2014 73 234 243 10.1097/NEN.0000000000000045 24487798 189. Williams I.M. Wallom K.L. Smith D.A. Al Eisa N. Smith C. Platt F.M. Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann-Pick disease type C1 mice Neurobiol. Dis. 2014 67 9 17 10.1016/j.nbd.2014.03.001 24631719 190. Marques A.R. Aten J. Ottenhoff R. van Roomen C.P. Herrera Moro D. Claessen N. Vinueza Veloz M.F. Zhou K. Lin Z. Mirzaian M. Reducing GBA2 Activity Ameliorates Neuropathology in Niemann-Pick Type C Mice PLoS ONE 2015 10 e0135889 10.1371/journal.pone.0135889 26275242 191. Cougnoux A. Clifford S. Salman A. Ng S.L. Bertin J. Porter F.D. Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin Mol. Genet. Metab. 2018 125 345 350 10.1016/j.ymgme.2018.10.009 30392741 192. Cougnoux A. Cluzeau C. Mitra S. Li R. Williams I. Burkert K. Xu X. Wassif C.A. Zheng W. Porter F.D. Necroptosis in Niemann-Pick disease, type C1: A potential therapeutic target Cell Death Dis. 2016 7 e2147 10.1038/cddis.2016.16 26986514 193. Kirkegaard T. Gray J. Priestman D.A. Wallom K.L. Atkins J. Olsen O.D. Klein A. Drndarski S. Petersen N.H. Ingemann L. Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses Sci. Transl. Med. 2016 8 355ra118 10.1126/scitranslmed.aad9823 194. Munkacsi A.B. Hammond N. Schneider R.T. Senanayake D.S. Higaki K. Lagutin K. Bloor S.J. Ory D.S. Maue R.A. Chen F.W. Normalization of Hepatic Homeostasis in the Npc1(nmf164) Mouse Model of Niemann-Pick Type C Disease Treated with the Histone Deacetylase Inhibitor Vorinostat J. Biol Chem. 2017 292 4395 4410 10.1074/jbc.M116.770578 28031458 195. Xie C. Gong X.M. Luo J. Li B.L. Song B.L. AAV9-NPC1 significantly ameliorates Purkinje cell death and behavioral abnormalities in mouse NPC disease J. Lipid Res. 2017 58 512 518 10.1194/jlr.M071274 28053186 196. Chandler R.J. Williams I.M. Gibson A.L. Davidson C.D. Incao A.A. Hubbard B.T. Porter F.D. Pavan W.J. Venditti C.P. Systemic AAV9 gene therapy improves the lifespan of mice with Niemann-Pick disease, type C1 Hum. Mol. Genet. 2017 26 52 64 10.1093/hmg/ddw367 27798114 197. Hughes M.P. Smith D.A. Morris L. Fletcher C. Colaco A. Huebecker M. Tordo J. Palomar N. Massaro G. Henckaerts E. AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease Hum. Mol. Genet. 2018 27 3079 3098 10.1093/hmg/ddy212 29878115 198. Markmann S. J J.C.-R. Rosenberg J.B. De B.P. Kaminsky S.M. Crystal R.G. Sondhi D. Attenuation of the Niemann-Pick type C2 disease phenotype by intracisternal administration of an AAVrh.10 vector expressing Npc2 Exp. Neurol. 2018 306 22 33 10.1016/j.expneurol.2018.04.001 29655638 199. Torres S. Matías N. Baulies A. Nuñez S. Alarcon-Vila C. Martinez L. Nuño N. Fernandez A. Caballeria J. Levade T. Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C disease Redox Biol. 2017 11 60 72 10.1016/j.redox.2016.11.010 27888692 200. Ferrante A. Pezzola A. Matteucci A. Di Biase A. Attorri L. Armida M. Martire A. Chern Y. Popoli P. The adenosine A(2A) receptor agonist T1-11 ameliorates neurovisceral symptoms and extends the lifespan of a mouse model of Niemann-Pick type C disease Neurobiol. Dis. 2018 110 1 11 10.1016/j.nbd.2017.10.013 29079454 201. Kulkarni A. Caporali P. Dolas A. Johny S. Goyal S. Dragotto J. Macone A. Jayaraman R. Fiorenza M.T. Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder Sci. Rep. 2018 8 9547 10.1038/s41598-018-27926-9 29934581 202. Houben T. Magro Dos Reis I. Oligschlaeger Y. Steinbusch H. Gijbels M.J.J. Hendrikx T. Binder C.J. Cassiman D. Westerterp M. Prickaerts J. Pneumococcal Immunization Reduces Neurological and Hepatic Symptoms in a Mouse Model for Niemann-Pick Type C1 Disease Front. Immunol. 2018 9 3089 10.3389/fimmu.2018.03089 30666257 203. Moreau D. Vacca F. Vossio S. Scott C. Colaco A. Paz Montoya J. Ferguson C. Damme M. Moniatte M. Parton R.G. Drug-induced increase in lysobisphosphatidic acid reduces the cholesterol overload in Niemann-Pick type C cells and mice EMBO Rep. 2019 20 e47055 10.15252/embr.201847055 31267706 204. Yasmin N. Ishitsuka Y. Fukaura M. Yamada Y. Nakahara S. Ishii A. Kondo Y. Takeo T. Nakagata N. Motoyama K. In Vitro and In Vivo Evaluation of 6-O-α-Maltosyl-β-Cyclodextrin as a Potential Therapeutic Agent Against Niemann-Pick Disease Type C Int. J. Mol. Sci. 2019 20 1152 10.3390/ijms20051152 205. Park M.H. Choi B.J. Jeong M.S. Lee J.Y. Jung I.K. Park K.H. Lee H.W. Yamaguchi T. Marti H.H. Lee B.H. Characterization of the Subventricular-Thalamo-Cortical Circuit in the NP-C Mouse Brain, and New Insights Regarding Treatment Mol. Ther. 2019 27 1507 1526 10.1016/j.ymthe.2019.05.008 31138511 206. Mitroi D.N. Pereyra-Gómez G. Soto-Huelin B. Senovilla F. Kobayashi T. Esteban J.A. Ledesma M.D. NPC1 enables cholesterol mobilization during long-term potentiation that can be restored in Niemann-Pick disease type C by CYP46A1 activation EMBO Rep. 2019 20 e48143 10.15252/embr.201948143 31535451 207. Schultz M.L. Fawaz M.V. Azaria R.D. Hollon T.C. Liu E.A. Kunkel T.J. Halseth T.A. Krus K.L. Ming R. Morin E.E. Synthetic high-density lipoprotein nanoparticles for the treatment of Niemann-Pick diseases BMC Med. 2019 17 200 10.1186/s12916-019-1423-5 31711490 208. Levy J.M. Yeh W.H. Pendse N. Davis J.R. Hennessey E. Butcher R. Koblan L.W. Comander J. Liu Q. Liu D.R. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses Nat. Biomed. Eng. 2020 4 97 110 10.1038/s41551-019-0501-5 31937940 209. Hung Y.H. Lotan A. Yeshurun S. Schroeder A. Bush A.I. Iron chelation by deferiprone does not rescue the Niemann-Pick Disease Type C1 mouse model Biometals 2020 33 87 95 10.1007/s10534-020-00233-5 32100150 210. Jiang D. Lee H. Pardridge W.M. Plasmid DNA gene therapy of the Niemann-Pick C1 mouse with transferrin receptor-targeted Trojan horse liposomes Sci. Rep. 2020 10 13334 10.1038/s41598-020-70290-w 32770132 211. Millat G. Marçais C. Rafi M.A. Yamamoto T. Morris J.A. Pentchev P.G. Ohno K. Wenger D.A. Vanier M.T. Niemann-Pick C1 disease: The I1061T substitution is a frequent mutant allele in patients of Western European descent and correlates with a classic juvenile phenotype Am. J. Hum. Genet. 1999 65 1321 1329 10.1086/302626 10521297 212. Park W.D. O’Brien J.F. Lundquist P.A. Kraft D.L. Vockley C.W. Karnes P.S. Patterson M.C. Snow K. Identification of 58 novel mutations in Niemann-Pick disease type C: Correlation with biochemical phenotype and importance of PTC1 -like domains in NPC1 Hum. Mutat. 2003 22 313 325 10.1002/humu.10255 12955717 213. Millat G. Marçais C. Tomasetto C. Chikh K. Fensom A.H. Harzer K. Wenger D.A. Ohno K. Vanier M.T. Niemann-Pick C1 disease: Correlations between NPC1 mutations, levels of NPC1 protein, and phenotypes emphasize the functional significance of the putative sterol-sensing domain and of the cysteine-rich luminal loop Am. J. Hum. Genet. 2001 68 1373 1385 10.1086/320606 11333381 214. Benussi A. Alberici A. Premi E. Bertasi V. Cotelli M.S. Turla M. Dardis A. Zampieri S. Marchina E. Paghera B. Phenotypic heterogeneity of Niemann-Pick disease type C in monozygotic twins J. Neurol. 2015 262 642 647 10.1007/s00415-014-7619-x 25536905 215. Miyawaki S. Yoshida H. Mitsuoka S. Enomoto H. Ikehara S. A mouse model for Niemann-Pick disease. Influence of genetic background on disease expression in spm/spm mice J. Hered 1986 77 379 384 10.1093/oxfordjournals.jhered.a110265 3559164 216. Zhang J. Erickson R.P. A modifier of Niemann Pick C 1 maps to mouse chromosome 19 Mamm. Genome 2000 11 69 71 10.1007/s003350010013 10602996 217. Parra J. Klein A.D. Castro J. Morales M.G. Mosqueira M. Valencia I. Cortés V. Rigotti A. Zanlungo S. Npc1 deficiency in the C57BL/6J genetic background enhances Niemann-Pick disease type C spleen pathology Biochem. Biophys. Res. Commun. 2011 413 400 406 10.1016/j.bbrc.2011.08.096 21910975 218. Marshall C.A. Watkins-Chow D.E. Palladino G. Deutsch G. Chandran K. Pavan W.J. Erickson R.P. In Niemann-Pick C1 mouse models, glial-only expression of the normal gene extends survival much further than do changes in genetic background or treatment with hydroxypropyl-beta-cyclodextrin Gene 2018 643 117 123 10.1016/j.gene.2017.12.006 29223359 219. Xie C. Turley S.D. Pentchev P.G. Dietschy J.M. Cholesterol balance and metabolism in mice with loss of function of Niemann-Pick C protein Am. J. Physiol 1999 276 E336 E344 10.1152/ajpendo.1999.276.2.E336 9950794 220. Xie C. Lund E.G. Turley S.D. Russell D.W. Dietschy J.M. Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration J. Lipid Res. 2003 44 1780 1789 10.1194/jlr.M300164-JLR200 12810827 221. Li H. Turley S.D. Liu B. Repa J.J. Dietschy J.M. GM2/GD2 and GM3 gangliosides have no effect on cellular cholesterol pools or turnover in normal or NPC1 mice J. Lipid Res. 2008 49 1816 1828 10.1194/jlr.M800180-JLR200 18450647 222. Kaptzan T. West S.A. Holicky E.L. Wheatley C.L. Marks D.L. Wang T. Peake K.B. Vance J. Walkley S.U. Pagano R.E. Development of a Rab9 transgenic mouse and its ability to increase the lifespan of a murine model of Niemann-Pick type C disease Am. J. Pathol. 2009 174 14 20 10.2353/ajpath.2009.080660 19056848 223. Maulik M. Ghoshal B. Kim J. Wang Y. Yang J. Westaway D. Kar S. Mutant human APP exacerbates pathology in a mouse model of NPC and its reversal by a beta-cyclodextrin Hum. Mol. Genet. 2012 21 4857 4875 10.1093/hmg/dds322 22869680 224. Jelinek D. Castillo J.J. Garver W.S. The C57BL/6J Niemann-Pick C1 mouse model with decreased gene dosage has impaired glucose tolerance independent of body weight Gene 2013 527 65 70 10.1016/j.gene.2013.05.080 23769925 225. Maulik M. Thinakaran G. Kar S. Alterations in gene expression in mutant amyloid precursor protein transgenic mice lacking Niemann-Pick type C1 protein PLoS ONE 2013 8 e54605 10.1371/journal.pone.0054605 23382922 226. Lee H. Lee J.K. Bae Y.C. Yang S.H. Okino N. Schuchman E.H. Yamashita T. Bae J.S. Jin H.K. Inhibition of GM3 synthase attenuates neuropathology of Niemann-Pick disease Type C. by affecting sphingolipid metabolism Mol. Cells 2014 37 161 171 10.14348/molcells.2014.2347 24599001 227. Chung C. Elrick M.J. Dell’Orco J.M. Qin Z.S. Kalyana-Sundaram S. Chinnaiyan A.M. Shakkottai V.G. Lieberman A.P. Heat Shock Protein Beta-1 Modifies Anterior to Posterior Purkinje Cell Vulnerability in a Mouse Model of Niemann-Pick Type C Disease PLoS Genet. 2016 12 e1006042 10.1371/journal.pgen.1006042 27152617 228. Lopez A.M. Jones R.D. Repa J.J. Turley S.D. Niemann-Pick C1-deficient mice lacking sterol O-acyltransferase 2 have less hepatic cholesterol entrapment and improved liver function Am. J. Physiol. Liver Physiol. 2018 315 G454 G463 10.1152/ajpgi.00124.2018 29878847 229. Shin S.D. Shin A. Mayagoitia K. Siebold L. Rubini M. Wilson C.G. Bellinger D.L. Soriano S. Loss of amyloid precursor protein exacerbates early inflammation in Niemann-Pick disease type C J. Neuroinflamm. 2019 16 269 10.1186/s12974-019-1663-5 31847862 230. Cawley N.X. Lyons A.T. Abebe D. Wassif C.A. Porter F.D. Evaluation of the Potential Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Niemann–Pick Disease, Type C1 Int. J. Mol. Sci. 2020 21 2430 10.3390/ijms21072430 231. Cougnoux A. Yerger J.C. Fellmeth M. Serra-Vinardell J. Martin K. Navid F. Iben J.R. Wassif C.A. Cawley N.X. Porter F.D. Single Cell Transcriptome Analysis of Niemann–Pick Disease, Type C1 Cerebella Int. J. Mol. Sci. 2020 21 5368 10.3390/ijms21155368 232. Klein A.D. De La Vega J.G. Zanlungo S. Complement Component C3 Participates in Early Stages of Niemann–Pick C Mouse Liver Damage Int. J. Mol. Sci. 2020 21 2127 10.3390/ijms21062127 233. Liu E.A. Schultz M.L. Mochida C. Chung C. Paulson H.L. Lieberman A.P. Fbxo2 mediates clearance of damaged lysosomes and modifies neurodegeneration in the Niemann-Pick C brain JCI Insight 2020 5 10.1172/jci.insight.136676 234. Ramirez C.M. Taylor A.M. Lopez A.M. Repa J.J. Turley S.D. Delineation of metabolic responses of Npc1(-/-nih) mice lacking the cholesterol-esterifying enzyme SOAT2 to acute treatment with 2-hydroxypropyl-β-cyclodextrin Steroids 2020 164 108725 10.1016/j.steroids.2020.108725 32890578 235. Smith A.F. Vanderah T.W. Erickson R.P. Haploinsufficiency of tau decreases survival of the mouse model of Niemann–Pick disease type C1 but does not alter tau phosphorylation J. Appl. Genet. 2020 61 567 570 10.1007/s13353-020-00572-6 32794098 236. Võikar V. Rauvala H. Ikonen E. Cognitive deficit and development of motor impairment in a mouse model of Niemann-Pick type C disease Behav. Brain Res. 2002 132 1 10 10.1016/S0166-4328(01)00380-1 11853852 237. Cougnoux A. Fellmeth M. Gu T. Davidson C.D. Gibson A.L. Pavan W.J. Porter F.D. Maternal immune activation modifies the course of Niemann-pick disease, type C1 in a gender specific manner Mol. Genet. Metab. 2020 129 165 170 10.1016/j.ymgme.2019.10.004 31668555 238. Houben T. Bitorina A.V. Oligschlaeger Y. Jeurissen M.L. Rensen S. Köhler S.E. Westerterp M. Lütjohann D. Theys J. Romano A. Sex-opposed inflammatory effects of 27-hydroxycholesterol are mediated via differences in estrogen signaling J. Pathol. 2020 251 429 439 10.1002/path.5477 32472585 239. Tchernof A. Després J.P. Pathophysiology of human visceral obesity: An update Physiol. Rev. 2013 93 359 404 10.1152/physrev.00033.2011 23303913 240. Regitz-Zagrosek V. Kararigas G. Mechanistic Pathways of Sex Differences in Cardiovascular Disease Physiol. Rev. 2017 97 1 37 10.1152/physrev.00021.2015 27807199 241. Lonardo A. Nascimbeni F. Ballestri S. Fairweather D. Win S. Than T.A. Abdelmalek M.F. Suzuki A. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps Hepatology 2019 70 1457 1469 10.1002/hep.30626 30924946 242. Mauvais-Jarvis F. Bairey Merz N. Barnes P.J. Brinton R.D. Carrero J.J. DeMeo D.L. De Vries G.J. Epperson C.N. Govindan R. Klein S.L. Sex and gender: Modifiers of health, disease, and medicine Lancet 2020 396 565 582 10.1016/S0140-6736(20)31561-0 32828189 243. Segatto M. Di Giovanni A. Marino M. Pallottini V. Analysis of the protein network of cholesterol homeostasis in different brain regions: An age and sex dependent perspective J. Cell Physiol. 2013 228 1561 1567 10.1002/jcp.24315 23280554 244. Tonini C. Segatto M. Pallottini V. Impact of Sex and Age on the Mevalonate Pathway in the Brain: A Focus on Effects Induced by Maternal Exposure to Exogenous Compounds Metab. 2020 10 304 10.3390/metabo10080304 245. Yu T. Shakkottai V.G. Chung C. Lieberman A.P. Temporal and cell-specific deletion establishes that neuronal Npc1 deficiency is sufficient to mediate neurodegeneration Hum. Mol. Genet. 2011 20 4440 4451 10.1093/hmg/ddr372 21856732 246. Yu T. Lieberman A.P. Npc1 acting in neurons and glia is essential for the formation and maintenance of CNS myelin PLoS Genet. 2013 9 e1003462 10.1371/journal.pgen.1003462 23593041 247. Borbon I. Totenhagen J. Fiorenza M.T. Canterini S. Ke W. Trouard T. Erickson R.P. Niemann-Pick C1 mice, a model of “juvenile Alzheimer’s disease”, with normal gene expression in neurons and fibrillary astrocytes show long term survival and delayed neurodegeneration J. Alzheimers Dis 2012 30 875 887 10.3233/JAD-2012-120199 22495346 248. Klein A.D. Oyarzún J.E. Cortez C. Zanlungo S. Gadolinium Chloride Rescues Niemann–Pick Type C Liver Damage Int. J. Mol. Sci. 2018 19 3599 10.3390/ijms19113599 249. Slezak M. Goritz C. Niemiec A. Frisen J. Chambon P. Metzger D. Pfrieger F.W. Transgenic mice for conditional gene manipulation in astroglial cells GLIA 2007 55 1565 1576 10.1002/glia.20570 17823970 250. Pfrieger F.W. Slezak M. Genetic approaches to study glial cells in the rodent brain GLIA 2012 60 681 701 10.1002/glia.22283 22162024 251. German D.C. Liang C.L. Song T. Yazdani U. Xie C. Dietschy J.M. Neurodegeneration in the Niemann-Pick C mouse: Glial involvement Neuroscience 2002 109 437 450 10.1016/S0306-4522(01)00517-6 11823057 252. Baudry M. Yao Y. Simmons D. Liu J. Bi X. Postnatal development of inflammation in a murine model of Niemann-Pick type C disease: Immunohistochemical observations of microglia and astroglia Exp. Neurol. 2003 184 887 903 10.1016/S0014-4886(03)00345-5 14769381 253. Kavetsky L. Green K.K. Boyle B.R. Yousufzai F.A.K. Padron Z.M. Melli S.E. Kuhnel V.L. Jackson H.M. Blanco R.E. Howell G.R. Increased interactions and engulfment of dendrites by microglia precede Purkinje cell degeneration in a mouse model of Niemann Pick Type-C Sci. Rep. 2019 9 14722 10.1038/s41598-019-51246-1 31605022 254. Walkley S.U. Pyramidal neurons with ectopic dendrites in storage diseases exhibit increased GM2 ganglioside immunoreactivity Neuroscience 1995 68 1027 1035 10.1016/0306-4522(95)00208-Z 8544979 255. March P.A. Thrall M.A. Brown D.E. Mitchell T.W. Lowenthal A.C. Walkley S.U. GABAergic neuroaxonal dystrophy and other cytopathological alterations in feline Niemann-Pick disease type C Acta Neuropathol. 1997 94 164 172 10.1007/s004010050689 9255392 256. Vite C.H. Ding W. Bryan C. O’Donnell P. Cullen K. Aleman D. Haskins M.E. Winkle T.V. Clinical, Electrophysiological, and Serum Biochemical Measures of Progressive Neurological and Hepatic Dysfunction in Feline Niemann-Pick Type C Disease Pediatraic Res. 2008 64 544 549 10.1203/PDR.0b013e318184d2ce 18614965 257. Bagel J.H. Sikora T.U. Prociuk M. Pesayco J.P. Mizisin A.P. Shelton G.D. Vite C.H. Electrodiagnostic testing and histopathologic changes confirm peripheral nervous system myelin abnormalities in the feline model of niemann-pick disease type C J. Neuropathol. Exp. Neurol. 2013 72 256 262 10.1097/NEN.0b013e318286587f 23399903 258. Roszell B.R. Tao J.-Q. Yu K.J. Gao L. Huang S. Ning Y. Feinstein S.I. Vite C.H. Bates S.R. Pulmonary Abnormalities in Animal Models Due to Niemann-Pick Type C1 (NPC1) or C2 (NPC2) Disease PLoS ONE 2013 8 e67084 10.1371/journal.pone.0067084 23843985 259. Mauler D.A. Gandolfi B. Reinero C.R. O’Brien D.P. Spooner J.L. Lyons L.A. Precision Medicine in Cats: Novel Niemann-Pick Type C1 Diagnosed by Whole-Genome Sequencing J. Vet. Intern. Med. 2017 31 539 544 10.1111/jvim.14599 28233346 260. Zampieri S. Bianchi E. Cantile C. Saleri R. Bembi B. Dardis A. Characterization of a Spontaneous Novel Mutation in the NPC2 Gene in a Cat Affected by Niemann Pick Type C Disease PLoS ONE 2014 9 e112503 10.1371/journal.pone.0112503 25396745 261. Sloan H.R. Uhlendorf B.W. Kanfer J.N. Brady R.O. Fredrickson D.S. Deficiency of sphingomyelin-cleaving enzyme activity in tissue cultures derived from patients with Niemann-Pick disease Biochem. Biophys. Res. Commun. 1969 34 582 588 10.1016/0006-291X(69)90777-3 5777777 262. Pentchev P.G. Boothe A.D. Kruth H.S. Weintroub H. Stivers J. Brady R.O. A genetic storage disorder in BALB/C mice with a metabolic block in esterification of exogenous cholesterol J. Biol. Chem. 1984 259 5784 5791 6325448 263. Liscum L. Faust J.R. Low density lipoprotein (LDL)-mediated suppression of cholesterol synthesis and LDL uptake is defective in Niemann-Pick type C fibroblasts J. Biol. Chem. 1987 262 17002 17008 3680287 264. Mazière C. Mazière J.C. Mora L. Lageron A. Polonovski C. Polonovski J. Alterations in cholesterol metabolism in cultured fibroblasts from patients with Niemann-Pick disease type C J. Inherit. Metab. Dis. 1987 10 339 346 10.1007/BF01799976 3126354 265. Carstea E.D. Morris J.A. Coleman K.G. Loftus S.K. Zhang D. Cummings C. Gu J. Rosenfeld M.A. Pavan W.J. Krizman D.B. Niemann-Pick C1 Disease Gene: Homology to Mediators of Cholesterol Homeostasis Science 1997 277 228 231 10.1126/science.277.5323.228 9211849 266. Gelsthorpe M.E. Baumann N. Millard E. Gale S.E. Langmade S.J. Schaffer J.E. Ory D.S. Niemann-Pick type C1 I1061T mutant encodes a functional protein that is selected for endoplasmic reticulum-associated degradation due to protein misfolding J. Biol. Chem. 2008 283 8229 8236 10.1074/jbc.M708735200 18216017 267. Liscum L. Faust J.R. The intracellular transport of low density lipoprotein-derived cholesterol is inhibited in Chinese hamster ovary cells cultured with 3-beta-[2-(diethylamino)ethoxy]androst-5-en-17-one J. Biol. Chem. 1989 264 11796 11806 2745416 268. Rodriguez-Lafrasse C. Rousson R. Bonnet J. Pentchev P.G. Louisot P. Vanier M.T. Abnormal cholesterol metabolism in imipramine-treated fibroblast cultures. Similarities with Niemann-Pick type C disease Biochim. Biophys. Acta 1990 1043 123 128 10.1016/0005-2760(90)90284-5 2317521 269. Roff C.F. Goldin E. Comly M.E. Cooney A. Brown A. Vanier M.T. Miller S.P. Brady R.O. Pentchev P.G. Type C Niemann-Pick disease: Use of hydrophobic amines to study defective cholesterol transport Dev. Neurosci. 1991 13 315 319 10.1159/000112179 1817037 270. Koh C.H. Cheung N.S. Cellular mechanism of U18666A-mediated apoptosis in cultured murine cortical neurons: Bridging Niemann-Pick disease type C and Alzheimer’s disease Cell Signal. 2006 18 1844 1853 10.1016/j.cellsig.2006.04.006 16797161 271. Cenedella R.J. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes Lipids 2009 44 477 487 10.1007/s11745-009-3305-7 19440746 272. Lu F. Liang Q. Abi-Mosleh L. Das A. De Brabander J.K. Goldstein J.L. Brown M.S. Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection eLife 2015 4 e12177 10.7554/eLife.12177 26646182 273. Levade T. Salvayre R. Lenoir G. Douste-Blazy L. Sphingomyelinase and nonspecific phosphodiesterase activities in Epstein-Barr virus-transformed lymphoid cell lines from Niemann-Pick disease A, B and C Biochim. Biophys. Acta 1984 793 321 324 10.1016/0005-2760(84)90337-0 6324871 274. Ohno K. Nanba E. Miyawaki S. Sakiyama T. Kitagawa T. Takeshita K. A cell line derived from sphingomyelinosis mouse shows alterations in intracellular cholesterol metabolism similar to those in type C Niemann-Pick disease Cell Struct. Funct. 1992 17 229 235 10.1247/csf.17.229 1394466 275. Byers D.M. Douglas J.A. Cook H.W. Palmer F.B. Ridgway N.D. Regulation of intracellular cholesterol metabolism is defective in lymphoblasts from Niemann-Pick type C and type D patients Biochim. Biophys. Acta 1994 1226 173 180 10.1016/0925-4439(94)90026-4 8204665 276. Brown A. Patel S. Ward C. Lorenz A. Ortiz M. DuRoss A. Wieghardt F. Esch A. Otten E.G. Heiser L.M. PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder Sci. Rep. 2016 6 31750 10.1038/srep31750 27572704 277. Huang L. Pike D. Sleat D.E. Nanda V. Lobel P. Potential pitfalls and solutions for use of fluorescent fusion proteins to study the lysosome PLoS ONE 2014 9 e88893 10.1371/journal.pone.0088893 24586430 278. Coleman E.M. Walker T.N. Hildreth J.E. Loss of Niemann Pick type C proteins 1 and 2 greatly enhances HIV infectivity and is associated with accumulation of HIV Gag and cholesterol in late endosomes/lysosomes Virol. J. 2012 9 31 10.1186/1743-422X-9-31 22273177 279. Cadigan K.M. Spillane D.M. Chang T.Y. Isolation and characterization of Chinese hamster ovary cell mutants defective in intracellular low density lipoprotein-cholesterol trafficking J. Cell Biol. 1990 110 295 308 10.1083/jcb.110.2.295 2404988 280. Dahl N.K. Reed K.L. Daunais M.A. Faust J.R. Liscum L. Isolation and characterization of Chinese hamster ovary cells defective in the intracellular metabolism of low density lipoprotein-derived cholesterol J. Biol. Chem. 1992 267 4889 4896 1537866 281. Higaki K. Ninomiya H. Sugimoto Y. Suzuki T. Taniguchi M. Niwa H. Pentchev P.G. Vanier M.T. Ohno K. Isolation of NPC1-deficient Chinese hamster ovary cell mutants by gene trap mutagenesis J. Biochem. 2001 129 875 880 10.1093/oxfordjournals.jbchem.a002932 11388901 282. Cruz J.C. Sugii S. Yu C. Chang T.Y. Role of Niemann-Pick type C1 protein in intracellular trafficking of low density lipoprotein-derived cholesterol J. Biol. Chem. 2000 275 4013 4021 10.1074/jbc.275.6.4013 10660558 283. Millard E.E. Srivastava K. Traub L.M. Schaffer J.E. Ory D.S. Niemann-pick type C1 (NPC1) overexpression alters cellular cholesterol homeostasis J. Biol. Chem. 2000 275 38445 38451 10.1074/jbc.M003180200 10964915 284. Ko D.C. Binkley J. Sidow A. Scott M.P. The integrity of a cholesterol-binding pocket in Niemann-Pick C2 protein is necessary to control lysosome cholesterol levels Proc. Natl. Acad. Sci. USA 2003 100 2518 2525 10.1073/pnas.0530027100 12591949 285. Ko D.C. Gordon M.D. Jin J.Y. Scott M.P. Dynamic movements of organelles containing Niemann-Pick C1 protein: NPC1 involvement in late endocytic events Mol. Biol. Cell 2001 12 601 614 10.1091/mbc.12.3.601 11251074 286. Zhang M. Dwyer N.K. Love D.C. Cooney A. Comly M. Neufeld E. Pentchev P.G. Blanchette-Mackie E.J. Hanover J.A. Cessation of rapid late endosomal tubulovesicular trafficking in Niemann-Pick type C1 disease Proc. Natl. Acad. Sci. USA 2001 98 4466 4471 10.1073/pnas.081070898 11296289 287. Wei J. Zhang Y.Y. Luo J. Wang J.Q. Zhou Y.X. Miao H.H. Shi X.J. Qu Y.X. Xu J. Li B.L. The GARP Complex Is Involved in Intracellular Cholesterol Transport via Targeting NPC2 to Lysosomes Cell Rep. 2017 19 2823 2835 10.1016/j.celrep.2017.06.012 28658628 288. Ebrahimi V. Hashemi A. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review Gene 2020 753 144813 10.1016/j.gene.2020.144813 32470504 289. Bartz F. Kern L. Erz D. Zhu M. Gilbert D. Meinhof T. Wirkner U. Erfle H. Muckenthaler M. Pepperkok R. Identification of cholesterol-regulating genes by targeted RNAi screening Cell Metab. 2009 10 63 75 10.1016/j.cmet.2009.05.009 19583955 290. Du X. Lukmantara I. Yang H. CRISPR/Cas9-Mediated Generation of Niemann-Pick C1 Knockout Cell Line Methods Mol. Biol. 2017 1583 73 83 28205168 291. Tharkeshwar A.K. Trekker J. Vermeire W. Pauwels J. Sannerud R. Priestman D.A. Te Vruchte D. Vints K. Baatsen P. Decuypere J.P. A novel approach to analyze lysosomal dysfunctions through subcellular proteomics and lipidomics: The case of NPC1 deficiency Sci. Rep. 2017 7 41408 10.1038/srep41408 28134274 292. Zhao K. Ridgway N.D. Oxysterol-Binding Protein-Related Protein 1L Regulates Cholesterol Egress from the Endo-Lysosomal System Cell Rep. 2017 19 1807 1818 10.1016/j.celrep.2017.05.028 28564600 293. Castellano B.M. Thelen A.M. Moldavski O. Feltes M. van der Welle R.E. Mydock-McGrane L. Jiang X. van Eijkeren R.J. Davis O.B. Louie S.M. Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex Science 2017 355 1306 1311 10.1126/science.aag1417 28336668 294. Rodríguez-Pascau L. Coll M.J. Casas J. Vilageliu L. Grinberg D. Generation of a human neuronal stable cell model for niemann-pick C disease by RNA interference JIMD Rep. 2012 4 29 37 23430894 295. Ulatowski L. Parker R. Davidson C. Yanjanin N. Kelley T.J. Corey D. Atkinson J. Porter F. Arai H. Walkley S.U. Altered vitamin E status in Niemann-Pick type C disease J. Lipid Res. 2011 52 1400 1410 10.1194/jlr.M015560 21550990 296. Twu Y.C. Lee T.S. Lin Y.L. Hsu S.M. Wang Y.H. Liao C.Y. Wang C.K. Liang Y.C. Liao Y.J. Niemann-Pick Type C2 Protein Mediates Hepatic Stellate Cells Activation by Regulating Free Cholesterol Accumulation Int. J. Mol. Sci. 2016 17 10.3390/ijms17071122 27420058 297. Davies J.P. Chen F.W. Ioannou Y.A. Transmembrane molecular pump activity of Niemann-Pick C1 protein Science 2000 290 2295 2298 10.1126/science.290.5500.2295 11125140 298. Maulik M. Peake K. Chung J. Wang Y. Vance J.E. Kar S. APP overexpression in the absence of NPC1 exacerbates metabolism of amyloidogenic proteins of Alzheimer’s disease Hum. Mol. Genet. 2015 24 7132 7150 10.1093/hmg/ddv413 26433932 299. Watabe K. Ida H. Uehara K. Oyanagi K. Sakamoto T. Tanaka J. Garver W.S. Miyawaki S. Ohno K. Eto Y. Establishment and characterization of immortalized Schwann cells from murine model of Niemann-Pick disease type C (spm/spm) J. Peripher. Nerv. Syst. 2001 6 85 94 10.1046/j.1529-8027.2001.01012.x 11446388 300. Erwood S. Brewer R.A. Bily T.M.I. Maino E. Zhou L. Cohn R.D. Ivakine E.A. Modeling Niemann-Pick disease type C in a human haploid cell line allows for patient variant characterization and clinical interpretation Genome Res. 2019 29 2010 2019 10.1101/gr.250720.119 31754021 301. Wang M.L. Motamed M. Infante R.E. Abi-Mosleh L. Kwon H.J. Brown M.S. Goldstein J.L. Identification of surface residues on Niemann-Pick C2 essential for hydrophobic handoff of cholesterol to NPC1 in lysosomes Cell Metab. 2010 12 166 173 10.1016/j.cmet.2010.05.016 20674861 302. Vanharanta L. Peränen J. Pfisterer S.G. Enkavi G. Vattulainen I. Ikonen E. High-content imaging and structure-based predictions reveal functional differences between Niemann-Pick C1 variants Traffic 2020 21 386 397 10.1111/tra.12727 32144825 303. Carette J.E. Raaben M. Wong A.C. Herbert A.S. Obernosterer G. Mulherkar N. Kuehne A.I. Kranzusch P.J. Griffin A.M. Ruthel G. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 Nature 2011 477 340 343 10.1038/nature10348 21866103 304. Côté M. Misasi J. Ren T. Bruchez A. Lee K. Filone C.M. Hensley L. Li Q. Ory D. Chandran K. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection Nature 2011 477 344 348 10.1038/nature10380 21866101 305. Stoeck I.K. Lee J.Y. Tabata K. Romero-Brey I. Paul D. Schult P. Lohmann V. Kaderali L. Bartenschlager R. Hepatitis C Virus Replication Depends on Endosomal Cholesterol Homeostasis J. Virol. 2018 92 e01196-17 10.1128/JVI.01196-17 29046459 306. Cahoy J.D. Emery B. Kaushal A. Foo L.C. Zamanian J.L. Christopherson K.S. Xing Y. Lubischer J.L. Krieg P.A. Krupenko S.A. A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function J. Neurosci. 2008 28 264 278 10.1523/JNEUROSCI.4178-07.2008 18171944 307. Foo L.C. Allen N.J. Bushong E.A. Ventura P.B. Chung W.S. Zhou L. Cahoy J.D. Daneman R. Zong H. Ellisman M.H. Development of a method for the purification and culture of rodent astrocytes Neuron 2011 71 799 811 10.1016/j.neuron.2011.07.022 21903074 308. Wohl S.G. Reh T.A. The microRNA expression profile of mouse Müller glia in vivo and in vitro Sci. Rep. 2016 6 35423 10.1038/srep35423 27739496 309. Bohlen C.J. Bennett F.C. Tucker A.F. Collins H.Y. Mulinyawe S.B. Barres B.A. Diverse Requirements for Microglial Survival, Specification, and Function Revealed by Defined-Medium Cultures Neuron 2017 94 759 773.e758 10.1016/j.neuron.2017.04.043 28521131 310. Sloan S.A. Darmanis S. Huber N. Khan T.A. Birey F. Caneda C. Reimer R. Quake S.R. Barres B.A. Paşca S.P. Human Astrocyte Maturation Captured in 3D Cerebral Cortical Spheroids Derived from Pluripotent Stem Cells Neuron 2017 95 779 790.e776 10.1016/j.neuron.2017.07.035 28817799 311. Falk T. Garver W.S. Erickson R.P. Wilson J.M. Yool A.J. Expression of Niemann-Pick type C transcript in rodent cerebellum in vivo and in vitro Brain Res. 1999 839 49 57 10.1016/S0006-8993(99)01678-9 10482798 312. Henderson L.P. Lin L. Prasad A. Paul C.A. Chang T.Y. Maue R.A. Embryonic striatal neurons from niemann-pick type C mice exhibit defects in cholesterol metabolism and neurotrophin responsiveness J. Biol. Chem. 2000 275 20179 20187 10.1074/jbc.M001793200 10770933 313. Karten B. Vance D.E. Campenot R.B. Vance J.E. Cholesterol accumulates in cell bodies, but is decreased in distal axons, of Niemann-Pick C1-deficient neurons J. Neurochem. 2002 83 1154 1163 10.1046/j.1471-4159.2002.01220.x 12437586 314. Jin L.W. Shie F.S. Maezawa I. Vincent I. Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities Am. J. Pathol. 2004 164 975 985 10.1016/S0002-9440(10)63185-9 14982851 315. Tashiro Y. Yamazaki T. Shimada Y. Ohno-Iwashita Y. Okamoto K. Axon-dominant localization of cell-surface cholesterol in cultured hippocampal neurons and its disappearance in Niemann-Pick type C model cells Eur. J. Neurosci. 2004 20 2015 2021 10.1111/j.1460-9568.2004.03677.x 15450080 316. Wasser C.R. Ertunc M. Liu X. Kavalali E.T. Cholesterol-dependent balance between evoked and spontaneous synaptic vesicle recycling J.Physiol 2007 579 413 429 10.1113/jphysiol.2006.123133 17170046 317. Demais V. Barthélémy A. Perraut M. Ungerer N. Keime C. Reibel S. Pfrieger F.W. Reversal of Pathologic Lipid Accumulation in NPC1-Deficient Neurons by Drug-Promoted Release of LAMP1-Coated Lamellar Inclusions J. Neurosci. 2016 36 8012 8025 10.1523/JNEUROSCI.0900-16.2016 27466344 318. Buard I. Pfrieger F.W. Relevance of neuronal and glial NPC1 for synaptic input to cerebellar Purkinje cells Mol. Cell Neurosci. 2014 61 65 71 10.1016/j.mcn.2014.06.003 24910948 319. Hawes C.M. Wiemer H. Krueger S.R. Karten B. Pre-synaptic defects of NPC1-deficient hippocampal neurons are not directly related to plasma membrane cholesterol J. Neurochem. 2010 114 311 322 10.1111/j.1471-4159.2010.06768.x 20456004 320. Suresh S. Yan Z. Patel R.C. Patel Y.C. Patel S.C. Cellular cholesterol storage in the Niemann-Pick disease type C mouse is associated with increased expression and defective processing of apolipoprotein D J. Neurochem. 1998 70 242 251 10.1046/j.1471-4159.1998.70010242.x 9422368 321. Strauss K. Goebel C. Runz H. Mobius W. Weiss S. Feussner I. Simons M. Schneider A. Exosome secretion ameliorates lysosomal storage of cholesterol in Niemann-Pick type C disease J. Biol. Chem. 2010 285 26279 26288 10.1074/jbc.M110.134775 20554533 322. Yang F. Feng X. Rolfs A. Luo J. Lovastatin promotes myelin formation in NPC1 mutant oligodendrocytes J. Neurol. Sci. 2018 386 56 63 10.1016/j.jns.2018.01.015 29406968 323. De Nuccio C. Bernardo A. Ferrante A. Pepponi R. Martire A. Falchi M. Visentin S. Popoli P. Minghetti L. Adenosine A(2A) receptor stimulation restores cell functions and differentiation in Niemann-Pick type C-like oligodendrocytes Sci. Rep. 2019 9 9782 10.1038/s41598-019-46268-8 31278313 324. Peake K.B. Campenot R.B. Vance D.E. Vance J.E. Niemann-Pick Type C1 deficiency in microglia does not cause neuron death in vitro Biochim. Biophys. Acta 2011 1812 1121 1129 10.1016/j.bbadis.2011.06.003 21704157 325. Seo Y. Kim H.S. Kang I. Choi S.W. Shin T.H. Shin J.H. Lee B.C. Lee J.Y. Kim J.J. Kook M.G. Cathepsin S contributes to microglia-mediated olfactory dysfunction through the regulation of Cx3cl1-Cx3cr1 axis in a Niemann-Pick disease type C1 model Glia 2016 64 2291 2305 10.1002/glia.23077 27687148 326. Walterfang M. Di Biase M.A. Cropley V.L. Scott A.M. O’Keefe G. Velakoulis D. Pathmaraj K. Ackermann U. Pantelis C. Imaging of neuroinflammation in adult Niemann-Pick type C disease: A cross-sectional study Neurology 2020 94 e1716 e1725 10.1212/WNL.0000000000009287 32209649 327. Marschalek N. Albert F. Meske V. Ohm T.G. The natural history of cerebellar degeneration of Niemann-Pick C mice monitored in vitro Neuropathol. Appl. Neurobiol. 2014 40 933 945 10.1111/nan.12154 24889722 328. Reid P.C. Sugii S. Chang T.Y. Trafficking defects in endogenously synthesized cholesterol in fibroblasts, macrophages, hepatocytes, and glial cells from Niemann-Pick type C1 mice J. Lipid Res. 2003 44 1010 1019 10.1194/jlr.M300009-JLR200 12611909 329. Vainio S. Bykov I. Hermansson M. Jokitalo E. Somerharju P. Ikonen E. Defective insulin receptor activation and altered lipid rafts in Niemann-Pick type C disease hepatocytes Biochem. J. 2005 391 465 472 10.1042/BJ20050460 15943586 330. Teratani T. Tomita K. Suzuki T. Oshikawa T. Yokoyama H. Shimamura K. Tominaga S. Hiroi S. Irie R. Okada Y. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells Gastroenterology 2012 142 152 164.e110 10.1053/j.gastro.2011.09.049 21995947 331. Te Vruchte D. Jeans A. Platt F.M. Sillence D.J. Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice J. Inherit. Metab. Dis. 2010 33 261 270 10.1007/s10545-010-9109-3 20458542 332. Zhang J.R. Coleman T. Langmade S.J. Scherrer D.E. Lane L. Lanier M.H. Feng C. Sands M.S. Schaffer J.E. Semenkovich C.F. Niemann-Pick C1 protects against atherosclerosis in mice via regulation of macrophage intracellular cholesterol trafficking J. Clin. Investig. 2008 118 2281 2290 10.1172/JCI32561 18483620 333. Roszell B.R. Tao J.Q. Yu K.J. Huang S. Bates S.R. Characterization of the Niemann-Pick C pathway in alveolar type II cells and lamellar bodies of the lung Am. J. Physiol. Lung Cell Mol. Physiol. 2012 302 L919 L932 10.1152/ajplung.00383.2011 22367786 334. Cougnoux A. Movassaghi M. Picache J.A. Iben J.R. Navid F. Salman A. Martin K. Farhat N.Y. Cluzeau C. Tseng W.C. Gastrointestinal Tract Pathology in a BALB/c Niemann-Pick Disease Type C1 Null Mouse Model Dig. Dis. Sci. 2018 63 870 880 10.1007/s10620-018-4914-x 29357083 335. Speak A.O. Platt N. Salio M. te Vruchte D. Smith D.A. Shepherd D. Veerapen N. Besra G.S. Yanjanin N.M. Simmons L. Invariant natural killer T cells are not affected by lysosomal storage in patients with Niemann-Pick disease type C Eur. J. Immunol. 2012 42 1886 1892 10.1002/eji.201141821 22585405 336. Pereira C.S. Pérez-Cabezas B. Ribeiro H. Maia M.L. Cardoso M.T. Dias A.F. Azevedo O. Ferreira M.F. Garcia P. Rodrigues E. Lipid Antigen Presentation by CD1b and CD1d in Lysosomal Storage Disease Patients Front. Immunol. 2019 10 1264 10.3389/fimmu.2019.01264 31214199 337. Sagiv Y. Hudspeth K. Mattner J. Schrantz N. Stern R.K. Zhou D. Savage P.B. Teyton L. Bendelac A. Cutting edge: Impaired glycosphingolipid trafficking and NKT cell development in mice lacking Niemann-Pick type C1 protein J. Immunol. 2006 177 26 30 10.4049/jimmunol.177.1.26 16785493 338. Platt N. Speak A.O. Colaco A. Gray J. Smith D.A. Williams I.M. Wallom K.L. Platt F.M. Immune dysfunction in Niemann-Pick disease type C J. Neurochem. 2016 136 74 80 10.1111/jnc.13138 25946402 339. Csepeggi C. Jiang M. Frolov A. Somatic cell plasticity and Niemann-pick type C2 protein: Adipocyte differentiation and function J. Biol. Chem. 2010 285 30347 30354 10.1074/jbc.M110.135939 20650896 340. Busso D. Oñate-Alvarado M.J. Balboa E. Castro J. Lizama C. Morales G. Vargas S. Härtel S. Moreno R.D. Zanlungo S. Spermatozoa from mice deficient in Niemann-Pick disease type C2 (NPC2) protein have defective cholesterol content and reduced in vitro fertilising ability Reprod. Fertil. Dev. 2014 26 609 621 10.1071/RD12059 24709320 341. Yang S.R. Kim S.J. Byun K.H. Hutchinson B. Lee B.H. Michikawa M. Lee Y.S. Kang K.S. NPC1 gene deficiency leads to lack of neural stem cell self-renewal and abnormal differentiation through activation of p38 mitogen-activated protein kinase signaling Stem. Cells 2006 24 292 298 10.1634/stemcells.2005-0221 16099992 342. Ordonez M.P. Roberts E.A. Kidwell C.U. Yuan S.H. Plaisted W.C. Goldstein L.S.B. Disruption and therapeutic rescue of autophagy in a human neuronal model of Niemann Pick type C1 Hum. Mol. Genet. 2012 21 2651 2662 10.1093/hmg/dds090 22437840 343. Bergamin N. Dardis A. Beltrami A. Cesselli D. Rigo S. Zampieri S. Domenis R. Bembi B. Beltrami C.A. A human neuronal model of Niemann Pick C disease developed from stem cells isolated from patient’s skin Orphanet. J. Rare Dis. 2013 8 34 10.1186/1750-1172-8-34 23433359 344. Trilck M. Hübner R. Seibler P. Klein C. Rolfs A. Frech M.J. Niemann-Pick type C1 patient-specific induced pluripotent stem cells display disease specific hallmarks Orphanet J. Rare Dis. 2013 8 144 10.1186/1750-1172-8-144 24044630 345. Lee H. Lee J.K. Park M.H. Hong Y.R. Marti H.H. Kim H. Okada Y. Otsu M. Seo E.J. Park J.H. Pathological roles of the VEGF/SphK pathway in Niemann-Pick type C neurons Nat. Commun. 2014 5 5514 10.1038/ncomms6514 25417698 346. Maetzel D. Sarkar S. Wang H. Abi-Mosleh L. Xu P. Cheng A.W. Gao Q. Mitalipova M. Jaenisch R. Genetic and Chemical Correction of Cholesterol Accumulation and Impaired Autophagy in Hepatic and Neural Cells Derived from Niemann-Pick Type C Patient-Specific iPS Cells Stem. Cell Rep. 2014 2 866 880 10.1016/j.stemcr.2014.03.014 24936472 347. Yu D. Swaroop M. Wang M. Baxa U. Yang R. Yan Y. Coksaygan T. DeTolla L. Marugan J.J. Austin C.P. Niemann-Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy J. Biomol. Screen 2014 19 1164 1173 10.1177/1087057114537378 24907126 348. Efthymiou A.G. Steiner J. Pavan W.J. Wincovitch S. Larson D.M. Porter F.D. Rao M.S. Malik N. Rescue of an in vitro neuron phenotype identified in Niemann-Pick disease, type C1 induced pluripotent stem cell-derived neurons by modulating the WNT pathway and calcium signaling Stem. Cells Transl. Med. 2015 4 230 238 10.5966/sctm.2014-0127 25637190 349. Völkner C. Peter F. Liedtke M. Krohn S. Lindner I. Murua Escobar H. Cimmaruta C. Lukas J. Hermann A. Frech M.J. Generation of the Niemann–Pick type C2 patient-derived iPSC line AKOSi001-A Stem. Cell Res. 2019 41 101606 10.1016/j.scr.2019.101606 31669975 350. Kuo S.Y. Castoreno A.B. Aldrich L.N. Lassen K.G. Goel G. Dančík V. Kuballa P. Latorre I. Conway K.L. Sarkar S. Small-molecule enhancers of autophagy modulate cellular disease phenotypes suggested by human genetics Proc. Natl. Acad. Sci. USA 2015 112 E4281 E4287 10.1073/pnas.1512289112 26195741 351. Gläser A. Hammerl F. Gräler M.H. Coldewey S.M. Völkner C. Frech M.J. Yang F. Luo J. Tönnies E. von Bohlen Und Halbach O. Identification of Brain-Specific Treatment Effects in NPC1 Disease by Focusing on Cellular and Molecular Changes of Sphingosine-1-Phosphate Metabolism Int. J. Mol. Sci. 2020 21 4520 10.3390/ijms21124502 352. Liscum L. Arnio E. Anthony M. Howley A. Sturley S.L. Agler M. Identification of a pharmaceutical compound that partially corrects the Niemann-Pick C phenotype in cultured cells J. Lipid Res. 2002 43 1708 1717 10.1194/jlr.M200179-JLR200 12364555 353. Swaroop M. Thorne N. Rao M.S. Austin C.P. McKew J.C. Zheng W. Evaluation of cholesterol reduction activity of methyl-beta-cyclodextrin using differentiated human neurons and astrocytes J. Biomol. Screen. 2012 17 1243 1251 10.1177/1087057112456877 22923786 354. Sung E.-A. Yu K.-R. Shin J.-H. Seo Y. Kim H.-S. Koog M.G. Kang I. Kim J.-J. Lee B.-C. Shin T.-H. Generation of patient specific human neural stem cells from Niemann-Pick disease type C patient-derived fibroblasts Oncotarget 2017 8 85428 85441 10.18632/oncotarget.19976 29156730 355. Pipalia N.H. Huang A. Ralph H. Rujoi M. Maxfield F.R. Automated microscopy screening for compounds that partially revert cholesterol accumulation in Niemann-Pick C cells J. Lipid Res. 2006 47 284 301 10.1194/jlr.M500388-JLR200 16288097 356. Xu M. Liu K. Swaroop M. Porter F.D. Sidhu R. Firnkes S. Ory D.S. Marugan J.J. Xiao J. Southall N. δ-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders J. Biol. Chem. 2012 287 39349 39360 10.1074/jbc.M112.357707 23035117 357. Pugach E.K. Feltes M. Kaufman R.J. Ory D.S. Bang A.G. High-content screen for modifiers of Niemann-Pick type C disease in patient cells Hum. Mol. Genet. 2018 27 2101 2112 10.1093/hmg/ddy117 29659804 358. Platt F.M. Neises G.R. Dwek R.A. Butters T.D. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis J. Biol. Chem. 1994 269 8362 8365 8132559 359. Cruz J.C. Chang T.Y. Fate of endogenously synthesized cholesterol in Niemann-Pick type C1 cells J. Biol. Chem. 2000 275 41309 41316 10.1074/jbc.M008272200 11013265 360. Zervas M. Somers K.L. Thrall M.A. Walkley S.U. Critical role for glycosphingolipids in Niemann-Pick disease type C Curr. Biol. 2001 11 1283 1287 10.1016/S0960-9822(01)00396-7 11525744 361. Crini G. Review: A history of cyclodextrins Chem Rev. 2014 114 10940 10975 10.1021/cr500081p 25247843 362. Camargo F. Erickson R.P. Garver W.S. Hossain G.S. Carbone P.N. Heidenreich R.A. Blanchard J. Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease Life Sci. 2001 70 131 142 10.1016/S0024-3205(01)01384-4 11787939 363. Davidson J. Molitor E. Moores S. Gale S.E. Subramanian K. Jiang X. Sidhu R. Kell P. Zhang J. Fujiwara H. 2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2019 1864 1545 1561 10.1016/j.bbalip.2019.04.011 31051283 364. Kao M.L. Stellar S. Solon E. Lordi A. Kasica N. Swain G. Bagel J.H. Gurda B.L. Vite C.H. Pharmacokinetics and distribution of 2-hydroxypropyl-β-cyclodextrin following a single intrathecal dose to cats J. Inherit. Metab. Dis. 2020 43 618 634 10.1002/jimd.12189 31707730 365. Pontikis C.C. Davidson C.D. Walkley S.U. Platt F.M. Begley D.J. Cyclodextrin alleviates neuronal storage of cholesterol in Niemann-Pick C disease without evidence of detectable blood-brain barrier permeability J. Inherit. Metab. Dis. 2013 36 491 498 10.1007/s10545-012-9583-x 23412751 366. Davidson C.D. Fishman Y.I. Puskas I. Szeman J. Sohajda T. McCauliff L.A. Sikora J. Storch J. Vanier M.T. Szente L. Efficacy and ototoxicity of different cyclodextrins in Niemann-Pick C disease Ann. Clin. Transl. Neurol. 2016 3 366 380 10.1002/acn3.306 27231706 367. Takahashi S. Homma K. Zhou Y. Nishimura S. Duan C. Chen J. Ahmad A. Cheatham M.A. Zheng J. Susceptibility of outer hair cells to cholesterol chelator 2-hydroxypropyl-β-cyclodextrine is prestin-dependent Sci Rep. 2016 6 21973 10.1038/srep21973 26903308 368. Cougnoux A. Drummond R.A. Collar A.L. Iben J.R. Salman A. Westgarth H. Wassif C.A. Cawley N.X. Farhat N.Y. Ozato K. Microglia activation in Niemann-Pick disease, type C1 is amendable to therapeutic intervention Hum. Mol. Genet. 2018 27 2076 2089 10.1093/hmg/ddy112 29617956 369. Ebner L. Gläser A. Bräuer A. Witt M. Wree A. Rolfs A. Frank M. Vollmar B. Kuhla A. Evaluation of Two Liver Treatment Strategies in a Mouse Model of Niemann-Pick-Disease Type C1 Int. J. Mol. Sci. 2018 19 972 10.3390/ijms19040972 29587349 370. Vacca F. Vossio S. Mercier V. Moreau D. Johnson S. Scott C.C. Montoya J.P. Moniatte M. Gruenberg J. Cyclodextrin triggers MCOLN1-dependent endo-lysosome secretion in Niemann-Pick type C cells J. Lipid Res. 2019 60 832 843 10.1194/jlr.M089979 30709900 371. Chen F.W. Li C. Ioannou Y.A. Cyclodextrin induces calcium-dependent lysosomal exocytosis PLoS ONE 2010 5 e15054 10.1371/journal.pone.0015054 21124786 372. Abi-Mosleh L. Infante R.E. Radhakrishnan A. Goldstein J.L. Brown M.S. Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells Proc. Natl. Acad. Sci. USA 2009 106 19316 19321 10.1073/pnas.0910916106 19884502 373. Rosenbaum A.I. Zhang G. Warren J.D. Maxfield F.R. Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells Proc. Natl. Acad. Sci. USA 2010 107 5477 5482 10.1073/pnas.0914309107 20212119 374. Wehrmann Z.T. Hulett T.W. Huegel K.L. Vaughan K.T. Wiest O. Helquist P. Goodson H. Quantitative comparison of the efficacy of various compounds in lowering intracellular cholesterol levels in niemann-pick type C fibroblasts PLoS.ONE 2012 7 e48561 10.1371/journal.pone.0048561 23144769 375. Peake K.B. Vance J.E. Normalization of cholesterol homeostasis by 2-hydroxypropyl-beta-cyclodextrin in neurons and glia from Niemann-Pick C1 (NPC1)-deficient mice J. Biol. Chem. 2012 287 9290 9298 10.1074/jbc.M111.326405 22277650 376. Meske V. Erz J. Priesnitz T. Ohm T.G. The autophagic defect in Niemann-Pick disease type C neurons differs from somatic cells and reduces neuronal viability Neurobiol. Dis. 2014 64 88 97 10.1016/j.nbd.2013.12.018 24412309 377. Sarkar S. Carroll B. Buganim Y. Maetzel D. Ng A.H. Cassady J.P. Cohen M.A. Chakraborty S. Wang H. Spooner E. Impaired autophagy in the lipid-storage disorder Niemann-Pick type C1 disease Cell Rep. 2013 5 1302 1315 10.1016/j.celrep.2013.10.042 24290752 378. Ory D.S. Ottinger E.A. Farhat N.Y. King K.A. Jiang X. Weissfeld L. Berry-Kravis E. Davidson C.D. Bianconi S. Keener L.A. Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: A non-randomised, open-label, phase 1-2 trial Lancet 2017 390 1758 1768 10.1016/S0140-6736(17)31465-4 28803710 379. Berry-Kravis E. Chin J. Hoffmann A. Winston A. Stoner R. LaGorio L. Friedmann K. Hernandez M. Ory D.S. Porter F.D. Long-Term Treatment of Niemann-Pick Type C1 Disease With Intrathecal 2-Hydroxypropyl-β-Cyclodextrin Pediatr. Neurol. 2018 80 24 34 10.1016/j.pediatrneurol.2017.12.014 29429782 380. Kim S.J. Lee B.H. Lee Y.S. Kang K.S. Defective cholesterol traffic and neuronal differentiation in neural stem cells of Niemann-Pick type C disease improved by valproic acid, a histone deacetylase inhibitor Biochem. Biophys. Res. Commun. 2007 360 593 599 10.1016/j.bbrc.2007.06.116 17624314 381. Pipalia N.H. Cosner C.C. Huang A. Chatterjee A. Bourbon P. Farley N. Helquist P. Wiest O. Maxfield F.R. Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts Proc. Natl. Acad. Sci. USA 2011 108 5620 5625 10.1073/pnas.1014890108 21436030 382. Nunes M.J. Moutinho M. Gama M.J. Rodrigues C.M. Rodrigues E. Histone deacetylase inhibition decreases cholesterol levels in neuronal cells by modulating key genes in cholesterol synthesis, uptake and efflux PLoS ONE 2013 8 e53394 10.1371/journal.pone.0053394 23326422 383. Newton J. Hait N.C. Maceyka M. Colaco A. Maczis M. Wassif C.A. Cougnoux A. Porter F.D. Milstien S. Platt N. FTY720/fingolimod increases NPC1 and NPC2 expression and reduces cholesterol and sphingolipid accumulation in Niemann-Pick type C mutant fibroblasts FASEB J. 2017 31 1719 1730 10.1096/fj.201601041R 28082351 384. Subramanian K. Hutt D.M. Scott S.M. Gupta V. Mao S. Balch W.E. Correction of Niemann-Pick type C1 trafficking and activity with the histone deacetylase inhibitor valproic acid J. Biol. Chem. 2020 295 8017 8035 10.1074/jbc.RA119.010524 32354745 385. Subramanian K. Rauniyar N. Lavalleé-Adam M. Yates J.R. 3rd Balch W.E. Quantitative Analysis of the Proteome Response to the Histone Deacetylase Inhibitor (HDACi) Vorinostat in Niemann-Pick Type C1 disease Mol. Cell Proteom. 2017 16 1938 1957 10.1074/mcp.M116.064949 28860124 386. Contreras P.S. Gonzalez-Zuñiga M. González-Hódar L. Yáñez M.J. Dulcey A. Marugan J. Seto E. Alvarez A.R. Zanlungo S. Neuronal gene repression in Niemann-Pick type C models is mediated by the c-Abl/HDAC2 signaling pathway Biochim. Biophys. Acta 2016 1859 269 279 10.1016/j.bbagrm.2015.11.006 26603102 387. Alam M.S. Getz M. Haldar K. Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model Sci. Transl. Med. 2016 8 326ra323 10.1126/scitranslmed.aad9407 26888431 388. Nakasone N. Nakamura Y.S. Higaki K. Oumi N. Ohno K. Ninomiya H. Endoplasmic reticulum-associated degradation of Niemann-Pick C1: Evidence for the role of heat shock proteins and identification of lysine residues that accept ubiquitin J. Biol. Chem. 2014 289 19714 19725 10.1074/jbc.M114.549915 24891511 389. Paul C.A. Reid P.C. Boegle A.K. Karten B. Zhang M. Jiang Z.G. Franz D. Lin L. Chang T.Y. Vance J.E. Adenovirus expressing an NPC1-GFP fusion gene corrects neuronal and nonneuronal defects associated with Niemann pick type C disease J. Neurosci. Res. 2005 81 706 719 10.1002/jnr.20592 16015597 390. Loftus S.K. Erickson R.P. Walkley S.U. Bryant M.A. Incao A. Heidenreich R.A. Pavan W.J. Rescue of neurodegeneration in Niemann-Pick C mice by a prion-promoter-driven Npc1 cDNA transgene Hum. Mol. Genet. 2002 11 3107 3114 10.1093/hmg/11.24.3107 12417532 391. Luo J. Yang H. Song B.L. Mechanisms and regulation of cholesterol homeostasis Nat. Rev. Mol. Cell Biol. 2020 21 225 245 10.1038/s41580-019-0190-7 31848472 392. Pfrieger F.W. Ungerer N. Cholesterol metabolism in neurons and astrocytes Prog. Lipid Res. 2011 50 357 371 10.1016/j.plipres.2011.06.002 21741992 393. Martin M.G. Pfrieger F. Dotti C.G. Cholesterol in brain disease: Sometimes determinant and frequently implicated EMBO Rep. 2014 15 1036 1052 10.15252/embr.201439225 25223281 394. Arenas F. Garcia-Ruiz C. Fernandez-Checa J.C. Intracellular Cholesterol Trafficking and Impact in Neurodegeneration Front. Mol. Neurosci. 2017 10 382 10.3389/fnmol.2017.00382 29204109 395. Lamri A. Pigeyre M. Garver W.S. Meyre D. The Extending Spectrum of NPC1-Related Human Disorders: From Niemann-Pick C1 Disease to Obesity Endocr. Rev. 2018 39 192 220 10.1210/er.2017-00176 29325023 396. Trezza V. Campolongo P. Vanderschuren L.J. Evaluating the rewarding nature of social interactions in laboratory animals Dev. Cogn. Neurosci. 2011 1 444 458 10.1016/j.dcn.2011.05.007 22436566 397. Halliwell J. Barbaric I. Andrews P.W. Acquired genetic changes in human pluripotent stem cells: Origins and consequences Nat. Rev. Mol. Cell Biol. 2020 21 715 728 10.1038/s41580-020-00292-z 32968234 398. Horvath P. Aulner N. Bickle M. Davies A.M. Nery E.D. Ebner D. Montoya M.C. Östling P. Pietiäinen V. Price L.S. Screening out irrelevant cell-based models of disease Nat. Rev. Drug Discov. 2016 15 751 769 10.1038/nrd.2016.175 27616293 399. Kim J. Koo B.K. Knoblich J.A. Human organoids: Model systems for human biology and medicine Nat. Rev. Mol. Cell Biol. 2020 21 571 584 10.1038/s41580-020-0259-3 32636524 400. Krystal J.H. State M.W. Psychiatric disorders: Diagnosis to therapy Cell 2014 157 201 214 10.1016/j.cell.2014.02.042 24679536 401. Becker R.E. Seeman M.V. Greig N.H. Lahiri D.K. What can triumphs and tribulations from drug research in Alzheimer’s disease tell us about the development of psychotropic drugs in general? Lancet Psychiatry 2015 2 756 764 10.1016/S2215-0366(15)00214-X 26249306 402. R Core Team R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing Vienna, Austria 2019 403. Dowle M. Data.Table: Extension of ‘Data.Frame’ Available online: https://CRAN.R-project.org/package=data.table (accessed on 25 November 2020) 404. Wickham H. Ggplot2: Elegant Graphics for Data Analysis Springer New York, NY, USA 2016 405. Wickham H. Readr: Read Rectangular Text Data Available online: https://cran.r-project.org/web/packages/readr/index.html (accessed on 25 November 2020)